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ABSTRACT	  Duchenne	   muscular	   dystrophy	   (DMD)	   is	   an	   X-­‐linked	   recessive	   neuromuscular	  disease	   that	   is	   the	   result	   of	   a	   loss	   of	   functional	   dystrophin,	   which	   causes	  cardiomyocyte	  fibrosis	  and	  death,	   leading	  to	  cardiomyopathy.	   In	  this	  thesis,	   I	  have	  utilized	   dynamic	   contrast-­‐enhanced	   computed	   tomography	   (DCE-­‐CT),	   positron	  emission	   tomography-­‐fluorodeoxyglucose	   (PET-­‐FDG),	   echocardiography,	   and	  traditional	   histology	   to	   longitudinally	   assess	   disease	   progression	   and	   degree	   of	  cardiomyopathy	   in	   a	  murine	  model	   of	   DMD	   (mdx:utrn-­‐/-­‐).	   No	   significant	   changes	  were	   observed	   in	   the	   blood	   flow,	   blood	   volume,	   or	   cardiac	   volume	  measured	   via	  DCE-­‐CT,	  nor	  in	  standard	  uptake	  value	  (SUV)	  of	  glucose	  as	  measured	  by	  PET-­‐FDG	  in	  the	  left	  myocardium	  between	  and	  within	  the	  two	  study	  groups	  (of	  mdx:utrn	  -­‐/-­‐	  mice	  	  and	   healthy	   wild-­‐type	   mice)	   over	   time.	   Our	   pilot	   echocardiography	   study	   and	  histological	   results	   show	   possible	   morphological/architectural	   and	   functional	  changes	  in	  affected	  myocardia	  of	  mdx:utrn-­‐/-­‐	  mice.	  These	  findings	  may	  provide	  us	  with	  an	  avenue	  to	  longitudinally	  characterize	  the	  progression	  of	  cardiomyopathy	  in	  the	   murine	   model	   of	   DMD,	   mdx:utrn	   -­‐/-­‐	   ,	   in	   addition	   to	   providing	   a	   potential	  baseline	   for	   a	   comparison	   with	   future	   therapeutics.	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1.0	  Introduction	  
Duchenne	  Muscular	  Dystrophy	  (DMD)	  is	  an	  X-­‐linked	  recessive	  neuromuscular	  disease	   that	   affects	   approximately	   1	   in	   3500	   males	   (1-­‐7).	   It	   is	   the	   second	   most	  common	   single	   gene	   disorder	   in	   Western	   countries	   (8),	   and	   it	   is	   one	   of	   the	  subcategories	   of	   muscular	   dystrophies,	   classified	   as	   a	   group	   of	   genetic	   disorders	  with	  progressive	  muscle	  weakness	  and	  wasting.	  To	  date,	  over	  30	  different	  types	  of	  muscular	  dystrophies	  have	  been	  identified	  and	  described	  (9).	  Duchenne	  muscular	  dystrophy	  is	  the	  most	  widespread	  form	  of	  dystrophy.	  It	  is	  named	   after	   the	   French	   neurologist,	   Guillaume	   Benjamin	   Duchenne,	   who	   first	  described	   the	   disease	   in	   1868	   (10).	   The	  majority	   of	   the	   clinical	   features	   of	   DMD	  result	   from	   the	   absence	   of	   membrane-­‐bound	   dystrophin,	   which	   brings	   about	   a	  complex	   chain	   of	   events	   that	   include	   skeletal	   muscle	   degeneration	   (11-­‐14),	   and	  cardiomyopathy	  (15-­‐19),	  the	  latter	  of	  which	  is	  the	  focus	  of	  this	  research	  study.	  	  Characterization	  of	  cardiomyopathy	  in	  DMD	  patients	  is	  of	  great	  importance,	  as	  it	   is	  present	  in	  over	  90%	  of	  patients,	  and	  greater	  than	  20%	  of	  DMD-­‐related	  deaths	  are	  due	  to	  cardiac	  failure	  (20,21).	  More	  specifically,	  25%	  of	  DMD	  patients	  under	  the	  age	   of	   6	   exhibit	   pre-­‐clinical	   cardiac	   involvement	   (for	   a	   detailed	   description	   see	  section	  1.2.2.2).	  This	  number	  rises	  to	  60%	  for	  patients	  between	  the	  ages	  of	  6	  to	  10.	  Clinically-­‐apparent	   cardiomyopathy	   is	  detectable	  at	   around	  10	  years	  of	   age	  and	   is	  present	  in	  nearly	  all	  the	  patients	  by	  18	  years	  of	  age	  (22).	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Due	   to	  enhanced	  ventilatory	  support,	   the	   life	  expectancy	  of	  DMD	  patients	  has	  progressively	  increased	  over	  the	  years,	  hence	  cardiac	  involvement	  dominates	  later	  stages	   of	   care	   management	   (23).	   The	   advancing	   age	   of	   DMD	   patients	   makes	  cardiomyopathy	  a	  high	  priority	  in	  care	  management,	  hence	  there	  is	  a	  critical	  need	  to	  develop	  non-­‐invasive	  methods	  to	   improve	  our	  current	  fundamental	  understanding	  of	  the	  progression	  of	  the	  disease.	  Use	  of	  imaging	  modalities	  DCE-­‐CT,	  PET-­‐FDG,	  and	  echocardiography,	  to	  fulfill	  this	  need,	  is	  the	  focus	  of	  this	  thesis.	  	  
1.1	  The	  myocardium,	  and	  cardiomyocytes	  
1.1.1	  The	  myocardium	  and	  cardiomyocytes	  Cardiac	  muscle	  (also	  termed	  myocardium)	  is	  an	  involuntary	  striated	  muscle.	  Cardiac	  cells	  (also	  termed	  cardiomyocytes	  or	  myocytes)	  are	  surrounded	  by	  a	  cell	  membrane	  termed	  the	  sarcolemma.	  Cardiomyocytes	  are	  attached	  to	  each	  other	  via	  intercalated	  disks	  (where	  the	  sarcolemmal	  membranes	  are	  joined	  to	  each	  other	  at	  desmosomes).	  The	   presence	   of	   gap	   junctions	   allows	   the	   spread	   of	   excitatory	   signals/action	  potentials	   from	   one	   cell	   to	   another	   (24).	   Like	   skeletal	  muscle,	   the	  myocardium	   is	  also	   comprised	   of	   contractile	   proteins,	   actin	   and	   myosin,	   which	   aid	   in	   muscle	  contraction.	   Furthermore,	   cardiac	   muscle	   requires	   the	   presence	   of	   extracellular	  calcium	   for	   its	   depolarization.	   A	   contraction	   involves	   an	   action	   potential	   that	   is	  generated	  by	   the	  sinoarterial	  and	  arterioventricular	  nodes	   that	   travels	  down	   from	  the	   non-­‐contracting	   cardiomyocytes	   to	   contracting	   cardiomyocytes.	   The	   action	  potential	   travels	   along	   the	   T-­‐tubules,	   which	   are	   deep	   invaginations	   of	   the	  sarcolemma,	   and	   triggers	   L-­‐type	   calcium	   channels	   and	   a	   subsequent	   influx	   of	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calcium	  into	  the	  cardiomyocytes.	  This	  initial	  influx	  of	  calcium	  causes	  further	  release	  of	   calcium	   (through	   positive	   feedback)	   from	   the	   sarcoplasmic	   reticulum	   to	   the	  cytosol	  through	  ryanodine	  receptors	  (25,26).	  Cytosolic	  calcium	  binds	  to	  troponin	  C,	  causing	   a	   conformational	   change	   and	   dislocation	   of	   both	   Troponin	   I	   and	  tropomyosin	   from	   the	   actin	   sites.	   This	   allows	  myosin	   to	   attach	   to	   actin,	   and	   as	   a	  result,	   contraction	   takes	   place.	   The	   contraction	   ends	   through	   the	   release	   of	   actin	  from	   myosin	   via	   release	   of	   calcium	   from	   the	   tropomyosin	   complex.	   Calcium	   is	  cleared	   from	   the	   cytosol	   by	   the	   action	   of	   a	   Na+/Ca2+	   exchanger	   and	   through	   the	  sarcoplasmic	  reticulum	  (SR)	  ATPase	  (which	  takes	  up	  the	  calcium	  into	  SR),	  leading	  to	  decreased	  levels	  of	  calcium	  within	  the	  cytosol	  (26,27).	  	  
1.1.2	  Cardiomyopathy	  Disease	   of	   the	   cardiomyocyte	   is	   termed	   cardiomyopathy.	   There	   are	   four	  different	  types	  of	  cardiomyopathy.	  The	  first	  type	  is	  arrhythmogenic	  right	  ventricular	  dysplasia	  (ARVD),	  which	  is	  a	  condition	  where	  the	  myocardium	  of	  the	  right	  ventricle	  is	   partially	   replaced	   by	   fatty	   and	   fibrous	   tissues.	   This	   inhibits	   the	   proper	  transmission	   of	   the	   electrical	   signal	   in	   the	   heart	   (28).	   The	   second	   type	   of	  cardiomyopathy	   is	   restrictive	   cardiomyopathy	   in	  which	   the	  myocardium	   loses	   its	  ability	  to	  relax	  in	  between	  contractions	  (during	  diastole).	  	  This	  is	  due	  to	  the	  rigidity	  of	   the	   cardiac	   walls	   (29).	   The	   third	   type	   of	   cardiomyopathy	   is	   hypertrophic	  cardiomyopathy	  which	   is	   characterized	  by	   thickening	  of	   the	  myocardial	  wall	  with	  disorganized	  fibers.	  This	  condition	  occurs	  as	  result	  of	  sacromeres	  increasing	  in	  size,	  causing	   thickening	   of	   the	   walls	   and	   misalignment	   of	   the	   cardiomyocytes.	   These	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events	  in	  turn	  prevent	  proper	  blood	  pumping	  and	  disrupt	  electrical	  signals	  (30,31).	  Prior	   to	   manifestation	   of	   clinical	   symptoms,	   most	   boys	   with	   DMD	   go	   through	   a	  hypertrophic	  cardiomyopathy	  stage	  (32).	  The	  fourth	  type	  is	  dilated	  cardiomyopathy	  and	   it	   is	   the	   most	   common	   form	   of	   cardiomyopathy.	   It	   is	   characterized	   by	   left	  ventricular	   dilation,	   and	   a	   corresponding	   increase	   in	   left	   ventricular	   volume.	   This	  thinning	   and	   stretching	   of	   the	   myocardium	   causes	   impairment	   to	   the	   systolic	  function	  of	  the	  heart	  (33).	  	  
1.2 Dystrophinopathies	  
1.2.1 General	  	  Dystrophinopathies	   are	   recessive	   forms	   of	   muscular	   dystrophies.	   They	   include	   a	  spectrum	  of	  muscle	  diseases	   that	  occur	  as	  a	  result	  of	  a	  deficiency	   in	  or	  absence	  of	  the	  cytoskeletal	  protein,	  dystrophin.	  In	  its	  mildest	  form,	  dystrophinopathies	  involve	  muscle	  cramps	  and	  isolated	  quadriceps	  myopathy	  (34).	  However,	  on	  the	  severe	  end	  of	  the	  spectrum,	  dystrophinopathies	  include	  Becker	  Muscular	  Dystrophy	  (BMD),	  X-­‐linked	  Dilated	  Cardiomyopathy	  (XLDC),	  and	  Duchenne	  muscular	  dystrophy	  (DMD).	  While	   XLDC	   has	   no	   skeletal	   muscle	   involvement,	   dilated	   cardiomyopathy	   is	   a	  common	   feature	   in	   both	   DMD	   and	   BMD.	   In	   BMD	   and	   DMD,	   cardiac	   involvement	  includes	   fibrosis	   and	   hypertrophy,	   leading	   to	   cardiomyopathy	   and	   cardiac	   failure	  (detailed	  description	  will	  follow	  in	  section	  1.2.2.2)	  (34,35).	  These	  characteristics	  are	  milder	  in	  BMD,	  due	  to	  a	  mutation	  in	  the	  dystrophin	  gene	  that	  does	  not	  cause	  a	  shift	  in	   the	   reading	   frame	   of	   the	   gene.	   Hence,	   the	   dystrophin	   protein	   is	   present	   but	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smaller	  in	  size.	  In	  contrast,	  the	  DMD	  mutation	  introduces	  an	  early	  stop	  codon	  in	  the	  dystrophin	  gene	  such	  that	  the	  dystrophin	  protein	  is	  absent	  (36).	  	  
1.2.2 Clinical	  Features	  of	  DMD	  
1.2.2.1	  Skeletal	  and	  other	  manifestations	  of	  DMD	  Children	  with	  DMD	  often	  have	  an	  unsteady	  gait	  and	  a	  developmental	  delay	  in	  walking(37).	   The	   clearest	   feature	   of	   disease	   onset	   is	   an	   enlargement	   of	   the	   calf	  muscles,	   deltoids,	   and	   quadriceps.	   As	   the	   disease	   progresses,	   lumbar	   lordosis	  becomes	   more	   apparent.	   Muscle	   weakness,	   in	   addition	   to	   muscle	   and	   joint	  shortening,	   also	   becomes	  more	   profound	   as	   the	   disease	   progresses.	   Furthermore,	  severe	   kyphoscoliosis	   develops,	   in	   addition	   to	   thoracic	   deformities	  which	   restrict	  proper	  pulmonary	  airflow	  (38).	  The	  weakening	  of	  the	  intercostal	  muscles	  escalates	  respiratory	  problems.	  	  At	  later	  stages	  of	  the	  disease,	  reduction	  of	  total	  lung	  capacity	  is	  followed	  by	  increased	  residual	  volume	  (39).	  	  
1.2.2.2	  Cardiac	  Manifestations	  of	  DMD	  Early	   stages	   of	   cardiomyopathy	   in	   patients	   involve	   cardiac	   arrhythmias.	  Additionally,	  mitral	   valve	   prolapse	   is	   observed	   in	   over	   a	   quarter	   of	   affected	   boys	  (40,41).	   Clinically-­‐detectable	   defects	   of	   cardiac	   function	   are	   first	   apparent	   in	  children	   around	   10	   years	   of	   age,	   with	   nearly	   all	   patients	   exhibiting	   clinically	  relevant	   cardiomyopathy	   by	   18	   years	   of	   age	   (16,19).	   Observed	   defects	   include	  impaired	  myocardial	  perfusion,	  reduction	  in	  the	  systolic	  and	  diastolic	  function,	  and	  conduction	  abnormalities.	  Degenerative	  changes	   that	   include	   fibrosis	  and	  necrosis	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as	   well	   as	   disordering	   of	   myofilaments	   have	   also	   been	   observed	   histologically	  (19,42-­‐44).	  	  	   Biopsies	  and	  histological	  analysis	  of	  cardiac	  muscle	  have	  shown	  features	  that	  parallel	  those	  observed	  in	  the	  skeletal	  muscle,	  including	  replacement	  of	  connective	  tissue	   with	   both	   fibrous	   and	   fatty	   infiltrations.	   Fibrosis,	   in	   particular,	   has	   been	  shown	  to	  originate	  in	  the	  outer	  myocardium	  involving	  the	  most	  posteriobasal	  aspect	  of	  the	  outer	  free	  wall	  of	  left	  myocardium.	  Initially,	  fibrosis	  is	  apparent	  in	  small	  areas,	  but	   they	  progressively	  become	  more	  diffuse,	  and	   involve	  most	  of	   the	  outer	  half	  of	  the	  ventricular	  wall	  (19,45,46).	  	  
1.3 Dystrophin	  and	  Dystrophin	  Glycoprotein	  Complex	  
(DGC)	  





Figure	  1.1	  Dystrophin	  and	  Dystrophin	  Associated	  Glycoprotein	  Complex.	  Dystrophin	  is	  part	  of	  Dystrophin	  Glycoprotein	  Complex	  (DGC)	  binding	  the	  F-­‐actin	  filaments	  to	  the	  extracellular	  matrix.	  Figure	  adapted	  from	  Roberts	  (2001)	  	  
1.3.2	  Lack	  of	  dystrophin	  from	  DGC	  and	  Sarcolemma	  	  In	  the	  absence	  of	  dystrophin	  in	  the	  DGC,	  a	  cascade	  of	  events	  is	  initiated	  that	  leads	  to	  cardiomyocyte	  death.	  More	  specifically,	  lack	  of	  functional	  dystrophin	  causes	  membrane	   destabilization	   and	   tearing	   due	   to	   muscle	   contractions.	   Furthermore,	  lack	  of	  functional	  dystrophin	  and	  tearing	  of	  the	  sarcolemma	  membrane	  up-­‐regulates	  stretch	  activated	  channels	  (SAC)	  and	  leads	  to	  an	  influx	  of	  extracellular	  calcium	  and	  release	   of	   intracellular	   calcium	   from	   the	   intracellular	   stores	   (54,55).	   Increasing	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intracellular	   calcium,	   in	   turn,	   activates	   calpains	   which	   degrade	   troponin	   I,	   and	  causes	  contractile	  dysfunction	  due	  to	  decreased	  calcium	  sensitivity.	  Cardiomyocyte	  death	   ensues,	   allowing	   infiltrating	   inflammatory	   cells	   and	   fibroblasts	   to	   enter	   the	  area	  to	  produce	  fibrosis	  and	  formation	  of	  scar	  tissue.	  It	  has	  been	  shown	  that	  in	  DMD,	  fibrosis	  starts	  at	  the	  epicardium	  of	  the	  left	  ventricular	  wall	  and	  advances	  toward	  the	  endocardium	   (55,56).	   Over	   time,	   fibrosis	   regions	   get	   thinner,	   stretch,	   and	   lose	  contractibility,	  leading	  to	  dilated	  cardiomyopathy.	  In	  addition,	  there	  is	  an	  increase	  in	  wall	   stress	   and	   left	   ventricular	   volume,	   as	   well	   as	   a	   decrease	   in	   cardiac	   output,	  diastolic	  relaxation,	  and	  contractility	  (55).	  
1.4 Animal	  Models	  of	  DMD	  
1.4.1	  General	  	  Homologs	   of	   DMD	   have	   been	   found	   in	   several	   species	   including	   fish,	   cats,	   dogs,	  invertebrates,	  and	  mice.	  	  Mammals	  have	  always	  been	  the	  preferred	  choice	  to	  study	  disease	   conditions	   of	   humans,	   due	   to	   similarities	   in	   anatomical	   and	   metabolic	  pathways.	  For	  example,	  not	  only	  do	  dogs	  possess	  similar	  body	  mass	  to	  humans,	  but	  there	   is	  also	  an	  extensive	  homology	   in	  disease	  pathogenesis	  between	  humans	  and	  dogs	   (specifically	   golden	   retriever	   DMD).	   This	   makes	   dogs	   a	   great	   choice	   for	  studying	   DMD.	   However,	   dogs	   are	   not	   ideal	   laboratory	   animals,	   colonies	   are	  expensive	   to	   maintain,	   and	   they	   cannot	   be	   easily	   genetically	   manipulated	   (57).	  Dystrophin	   deficient	   cats	   also	   exhibit	   cardiomyopathy.	   However,	   most	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characteristics	  of	  DMD	  are	  not	  present	  in	  this	  animal	  model,	  preventing	  them	  from	  also	  being	  an	  optimal	  animal	  model	  for	  studying	  this	  disease	  (57,58).	  	  
1.4.2	  Mouse	  models	  
1.4.2.1	  Mdx	  mice	  Mouse	  models	  are	  the	  most	  commonly	  used	  laboratory	  model	  of	  DMD	  due	  to	  their	  size	  and	  ability	  to	  be	  genetically	  manipulated.	  The	  most	  common	  mouse	  model	  is	   the	   X	   chromosome-­‐linked	   muscular	   dystrophy	   (mdx)	   mouse,	   in	   which	   the	  expression	   of	   dystrophin	   is	   eliminated	   due	   to	   a	   point	  mutation	   in	   the	   dystrophin	  gene	   (17,59).	   These	  mice	   exhibit	   histological	   signs	   of	   muscular	   dystrophy	   during	  their	   first	   6	   weeks	   of	   life;	   however,	   the	   subsequent	   course	   of	   their	   disease	   is	  different	   from	   what	   is	   observed	   in	   DMD	   patients.	   Indeed,	   mdx	   mice	   have	   near	  normal	  life	  spans,	  show	  little	  weakness,	  and	  do	  not	  develop	  severe	  myofibrosis(19).	  	  Onset	   of	   cardiac	   abnormality	   is	   also	   delayed	   in	   mdx	   mice;	   as	   shown	   via	  echocardiography	  and	  left	  heart	  catherization	  (Quinlan	  et	  al.	  (2004)),	  fibrosis	  is	  less	  severe	   in	   these	   mice	   (32).	   This	   has	   been	   shown	   to	   be	   partly	   due	   to	   the	  compensatory	   effects	   of	   utrophin,	   which	   acts	   as	   a	   homolog	   to	   dystrophin	   (17).	  Furthermore,	  studies	  have	  shown	  that	  regenerating	  DMD	  areas	  with	  the	  highest	  up-­‐regulation	   of	   utrophin	   (normally	   present	   in	   the	   postsynaptic	   membrane	   at	   the	  neuromuscular	   junction)	   show	   the	   least	   extent	   of	   pathological	   changes	   such	   as	  degeneration	   and	   necrosis.	   When	   expressed	   at	   high	   levels,	   utrophin	   can	   fully	  compensate	  for	  dystrophin	  (19,60).	  These	  differences	  have	  thus	  limited	  the	  utility	  of	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mdx	   mice	   as	   a	   model	   for	   studying	   both	   cardiomyopathy	   and	   skeletal	   muscle	  pathology.	  	  
	  




1.5	  Medical	  Imaging	  Modalities	  Used	  in	  Characterization	  of	  
DMD	  
Medical	   Imaging	   is	   a	   process	   whereby	   visual	   representations	   of	   the	   body	  parts,	  tissues,	  and	  organs	  are	  created	  to	  study	  its	  function,	  anatomy,	  and	  biological	  processes.	   Early	   methods	   of	   studying	   pathology	   and	   the	   progression	   of	   DMD	  consisted	  of	  blood	  tests,	  and	  painful	  invasive	  biopsies.	  However,	  recent	  advances	  in	  medical	   imaging	   now	   provide	   us	   with	   an	   ability	   to	   diagnose,	   monitor,	   and	   study	  disease	   progression	   non-­‐invasively.	   To	   date,	   a	   variety	   of	   imaging	  modalities	   have	  been	  used	  to	  study	  DMD,	  each	  with	  its	  own	  strengths	  and	  weaknesses.	  For	  example,	  research	   conducted	   by	   Perloff	   et	   al.	   (1984)	   and	   Quinlivan	   et	   al.	   (1996)	   to	   study	  alterations	   in	  myocardial	  metabolism,	  perfusion,	  wall	  motion,	  and	  cardiac	   function	  in	  DMD	  patients	  using	  radionuclides	  and	  positron	  emission	  tomography	  (PET),	  have	  identified	  abnormalities	  in	  the	  myocardium	  and	  metabolism/perfusion	  mismatches	  (18,44).	  More	  specifically,	  Perloff	  et	  al.	  (1984),	  used	  PET	  to	  demonstrate	  that	  there	  is	  an	  increase	  in	  glucose	  uptake	  in	  the	  posteriolateral	  and	  posteriobasal	  wall	  of	  the	  left	   ventricle.	   In	   addition,	  Quinlivan	  et	   al.	   (1996),	   also	  using	  PET	  have	   shown	   that	  there	   are	   perfusion	   defects	   in	   the	   area	   of	   inferior,	   and	   anterior	   regions	   of	   left	  ventricle.	   This	   study	   further	   demonstrates	   that	   in	   the	   majority	   of	   DMD	   patients,	  there	   is	   a	   mismatch	   between	   perfusion	   and	   glucose	   uptake	   in	   the	   myocardium,	  suggesting	  that	  these	  differences	  may	  be	  due	  to	  myocardial	  ischemia.	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Echocardiography	  has	  also	  been	  used	  to	  measure	  cardiac	  function	  in	  studies	  involving	   DMD	   patients,	   demonstrating	   patterns	   of	   cardiac	   involvement	   in	   the	  disease	  which	   encompasses	   left	   ventricular	   dilation	   and	  decrease	   in	   function	   (64-­‐67).	   Previously,	   echocardiography	  was	   used	   to	  measure	   left	   ventricular	   posterior	  wall	   motion	   abnormalities	   in	   Duchenne	   muscular	   dystrophy	   (32,64-­‐68).	   A	   study	  conducted	   by	   Quinlan	   et	   al.	   (2004)	   has	   described	   use	   of	   echocardiography	   to	  measure	  the	  evolution	  of	  cardiomyopathy	  in	  mdx	  mice	  and	  demonstrated	  that	  there	  are	  important	  clinical	  features	  that	  are	  shared	  between	  the	  mdx	  mouse	  model	  and	  cardiomyopathy	   in	   DMD	   patients.	   These	   shared	   clinical	   features	   include	  cardiomyocyte	   hypertrophy	   and	   necrosis,	   as	   well	   as	   cardiac	   fibrosis	   (32).	  Furthermore	   a	   study	   conducted	   by	   Chetboul	   et	   al.	   (2004)	   used	   tissue	   Doppler	  imaging	   to	  detect	  myocardial	  abnormalities	   in	  a	  dog	  model	  of	  Duchenne	  muscular	  dystrophy.	  They	  have	  shown	  that	  there	  is	  a	  decrease	  in	  systolic	  and	  early	  diastolic	  myocardial	   velocity	   gradient	   and	   that	   the	   sensitivity	   of	  Doppler	   imaging	   is	   higher	  than	   conventional	   method	   of	   echocardiography	   when	   pre-­‐clinical	   cardiac	  abnormalities	  are	  detected	  (69).	  	  In	   a	   previous	   study	   conducted	   by	   our	   group	   (Ahmad	   et	   al.	   (2011)),	   we	  utilized	  imaging	  modalities	  of	  DCE-­‐CT	  and	  PET-­‐FDG	  to	  assess	  perfusion	  and	  glucose	  metabolism	   in	   the	   skeletal	   muscle	   of	   both	   mdx	   and	   mdx:utrn	   -­‐/-­‐	   mice.	   It	   was	  observed,	  that	  there	  is	  an	  initial	  peak	  followed	  by	  a	  decrease	  in	  the	  blood	  flow	  (BF),	  blood	  volume	  (BV)	  and	  glucose	  uptake	  (9).	  DCE-­‐CT	  was	  utilized	  based	  on	  previous	  studies	  showing	  that	  in	  DMD,	  neuronal	  nitric	  oxide	  synthase	  (nNOS)	  mislocalization	  produces	  ischemia	  (70).	  Thus,	  measuring	  BF	  and	  BV	  via	  DCE-­‐CT	  may	  be	  indicative,	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of	   the	   degree	   of	   ischemia	   and	   overall	   skeletal	   muscle	   condition.	   Healthy	   muscle	  readily	  metabolized	  glucose;	  thus	  reduced	  18F-­‐FDG	  uptake	  might	  also	  be	  indicative	  of	  disease	  pathology.	  	  There	  is	  a	  necessity	  for	  the	  use	  of	  preclinical,	  small	  animal	  models	  in	  the	  area	  of	   imaging	   technology.	   Use	   of	   these	   models	   will	   allow	   us	   to	   better	   understand	  disease	  pathogenesis	  such	  that	  we	  can	  intervene	  and	  treat	  disease	  at	  an	  earlier	  stage	  or	   to	   slow	   its	  progression.	   In	   this	   study,	   the	   imaging	  modalities	  DCE-­‐CT,	  PET-­‐FDG	  and	  echocardiography	  were	  utilized	   to	   longitudinally	  study	  disease	  progression	   in	  the	   myocardia	   of	   mdx:utrn	   -­‐/-­‐	   mice,	   and	   furthermore,	   to	   provide	   a	   baseline	   for	  comparison	  when	  monitoring	  the	  success/failure	  of	  future	  therapeutics.	  
1.5.1	  Dynamic	  Contrast	  Enhanced	  Computed	  Tomography	  (DCE-­‐CT)	  Dynamic	  contrast	  enhanced	  computed	  tomography	  (DCE-­‐CT)	  uses	  a	  series	  of	  CT	   scans	   at	   the	   same	   location	   to	   study	   the	   distribution	   of	   a	   contrast	   agent	   in	   the	  myocardium	  as	  a	  function	  of	  time.	  Dynamic	  CT	  has	  become	  the	  dominant	  CT	  method	  in	  clinical	  evaluation	  of	  physiological	  function	  (71)	  .	  One	  of	  the	  main	  advantages	  of	  functional	  CT	  over	  other	  modalities,	  has	  been	  its	  simplicity	  and	  accessibility	  (71).	  The	   intensity	   of	   the	  CT	   image,	  which	   is	   expressed	   as	   a	  Houndsfield	  unit,	   is	  determined	   by	   the	   efficiency	   with	   which	   the	   x-­‐ray	   is	   attenuated	   (71,72).	   In	  functional	   CT,	   the	   iodine	   based	   contrast	   agent	   is	   injected	   intravenously,	   and	   an	  increase	   in	   the	   attenuation	   or	   enhancement	   of	   tissue	   contrast	   following	   arrival	   of	  the	  contrast	  agent	  is	  measured	  (71,73).	  An	  Initial	  data	  processing	  step	  is	  to	  subtract	  the	   baseline	   image	   intensity	   from	   the	   image	   intensities	   following	   arrival	   of	   the	  contrast	  agent.	  This	  subtraction	  of	  baseline	  scans	  from	  the	  scans	  following	  arrival	  of	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the	   contrast	   agent,	   provides	   a	   time-­‐density	   curve	   (TDC)	   or	   time-­‐versus-­‐enhancement	  curve.	  A	  baseline	  scan,	  followed	  by	  series	  of	  scans	  until	  the	  clearance	  of	  the	  contrast	  agent	  from	  the	  tissue,	  is	  conducted.	  	  In	   a	   DCE-­‐CT	   study,	   x-­‐ray	   iodine	   based	   contrast	   agents	   are	   injected	   via	   a	  peripheral	  vein	  into	  the	  blood	  stream.	  Using	  CT,	  the	  tissue	  concentration,	  Q(t),	  and	  the	  arterial	  concentration,	  Ca(t)	  are	  measured	  (9,71-­‐73).	  The	  basis	  of	  this	  technique	  is	  dependent	  on	  the	  assumption	  that	  contrast	  enhancement	  of	  the	  region	  relies	  on	  the	  tracer	  concentration,	  and	  that	  the	  tracer	  is	  uniformly	  distributed	  in	  the	  ventricle.	  Using	   the	   appropriate	   tracer	   kinetic	   models	   in	   conjunction	   with	   acquired	   data,	  hemodynamic	  information	  in	  regards	  to	  tissue	  blood	  flow	  and	  tissue	  blood	  volume	  is	  extracted	  (9).	  	  The	  algorithm	  used	  in	  CT	  perfusion	  is	  based	  on	  the	  Johnson	  Wilson	  model,	  a	  distributed	   compartmental	   model	   with	   bidirectional	   flow	   (72,74).	   The	   model	  divides	  the	  myocardium	  in	  two	  principal	  spaces:	  the	  extra-­‐vascular	  space	  (EVS)	  and	  intravascular	   space	   (IVS),	   which	   are	   separated	   by	   the	   permeable	   capillary	  endothelium.	   This	   model	   is	   based	   on	   three	   assumptions.	   First,	   there	   is	   a	  homogenous	   spatial	   distribution	   of	   tracer	   concentration	   within	   the	   EVS.	   Second,	  there	   is	   bidirectional	   diffusion	   of	   contrast	   between	   EVS	   and	   IVS.	   Third,	   within	  capillaries	   there	   is	   axial	   concentration	   gradient	   of	   contrast,	   however	   the	   radial	  concentration	  gradient	  is	  negligible.	  Furthermore,	  adiabatic	  approximation,	  derived	  by	   St.	   Lawrence	   and	   Lee	   (1998),	   assumes	   that	   the	   EVS	   contrast	   concentration	  changes	  at	  slower	  rate	  relative	  to	  IVS.	  (9,72)	  The	  parametric	  maps	  are	  created	  using	  the	   GE	   Workstation	   (GE	   healthcare)	   with	   use	   of	   its	   proprietary	   software	   (CT	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Figure	  1.2	  Blood	  flow	  scaled	  Impulse	  residue	  function,	  (F.R(t))	  reflecting	  mass	  of	  contrast	  medium	  remaining	  in	  tissue.	  Vb	  depicts	  blood	  volume	  and	  F	  represents	  blood	  flow.	  Figure	  adapted	  from	  Sahani	  et.	  al.	  (2005)	  (73)	  	  
1.5.2	  Positron	  Emission	  Tomography	  (PET)	  Positron	  Emission	  Tomography	  (PET)	  was	  first	  introduced	  in	  1975,	  and	  has	  since	  been	  used	  for	  non-­‐invasive	  imaging	  of	  the	  heart	  (75,76).	  	  Indeed,	  PET	  has	  been	  considered	   to	   be	   the	   gold	   standard	   for	   noninvasive	   assessment	   of	   myocardial	  viability	   and	   perfusion.	   This	   is	   due	   to	   its	   superior	   sensitivity	   and	   its	   quantitative	  nature.	  	  In	  PET,	  a	  positron	  emitting	  radio-­‐nucleotide	  labeled	  chemical	  compound	  (in	  this	  study	  18F-­‐Fluorodeoxyglucose	  (18F-­‐FDG)	  was	  used)	  is	  injected	  into	  the	  body.	  As	  the	  radio-­‐nucleotide	  decays,	  positrons	  are	  emitted,	  which	  after	  traveling	  for	  a	  short	  distance	   and	   losing	   energy,	   annihilate	  with	   the	   electron	   and	   produce	   two	   gamma	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rays	  with	  energy	  of	  511	  keV	  travelling	  at	  opposite	  directions.	  These	  gamma	  rays	  are	  detected	  on	  opposite	  sides	  by	  the	  photomultiplier-­‐scintillating	  detectors	  placed	  in	  a	  ring	   around	   the	   body.	   Scintillating	   crystals	   convert	   the	   gamma	   photons	   to	   light,	  which	   furthermore	   is	   multiplied	   and	   converted	   to	   electrical	   signal	   by	   the	  photomultiplier	  tube.	  To	  determine	  whether	  two	  signals	  are	  from	  the	  same	  source,	  coincidence	  processing	  is	  performed.	  If	  photons	  do	  not	  arrive	  within	  temporal	  pairs	  (within	   a	   timing	  window	   of	   a	   few	   nanoseconds),	   the	   photons	   and	   its	   subsequent	  signal	   are	   ignored.	   The	   coincidence	   event	   is	   assigned	   to	   a	   line	   of	   response	   (LOR),	  which	   joins	   two	   relevant	  detectors.	  The	   coincidence	  events	   are	   stored	   in	   forms	  of	  arrays	   corresponding	   to	   the	   projection	   through	   the	   body	   and	   the	   image	   is	  reconstructed	  using	  standard	   tomographic	   technique	  (77-­‐79).	   In	  PET-­‐FDG	  studies,	  the	  intensity	  of	  the	  image	  is	  proportional	  to	  uptake	  concentration	  of	  18F-­‐FDG	  in	  the	  tissue	  of	  study,	  here	  the	  myocardium	  (79).	  	  
1.5.3	  Echocardiography	  Echocardiography	   (also	   known	   as	   cardiac	   ultrasound)	   is	   a	   diagnostic	  technique,	   which	   uses	   ultrasound	   to	  measure	   the	   anatomy	   and	   physiology	   of	   the	  heart.	   Ultrasound,	   refers	   to	   frequencies	   that	   are	   above	   20,000	   Hz,	   and	   are	   not	  audible	  by	  the	  human	  ear.	  Cardiac	  imaging	  applications	  use	  ultrasound	  frequencies	  of	  1-­‐20	  MHz	  range	  (80).	  	  In	   echocardiography,	   an	   ultrasound	   pulse	   is	   sent	   and	   received	   via	   a	  transducer,	  which	  uses	  piezoelectric	  material	   to	   convert	   sound	   to	   electrical	   signal	  and	   vice	   versa.	  As	   the	   sound	   travels	   though	   the	   body,	   it	   is	   partly	   reflected	  by	   the	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tissue	   interphases	   (where	   the	   acoustic	   properties	   change),	   and	   these	   reflected	  pulses	  are	   received	  by	   the	   transducer	  and	  converted	   to	  electrical	   signal.	   Since	   the	  speed	  of	  signal	  is	  known	  in	  the	  tissue	  (to	  be	  approximately	  1540	  m/s	  in	  soft	  tissue),	  the	  approximate	  location	  can	  be	  determined	  by	  using	  time	  of	  travel	  of	  the	  pulse.	  The	  grey	   scale	   display	   of	   amplitude	  over	  depth	   information	   from	   scan	   lines	   is	   created	  (80,81).	  The	  amplitude	  of	  the	  pulse	  decreases	  as	  it	  travels	  through	  the	  tissue	  due	  to	  reflection,	   scatter	   and	   absorbance.	   Higher	   resolution	   images	   can	   be	   obtained	   by	  increasing	   the	   frequency	   of	   the	   pulse;	   however	   increasing	   the	   frequency	   would	  decrease	  its	  penetration	  depth	  in	  the	  tissue.	  	  
1.6	  Research	  Outline	  
The	  goal	  of	  this	  research	  project	  was	  to	  longitudinally	  characterize	  the	  progression	  of	  cardiomyopathy	  in	  the	  murine	  model	  of	  DMD:	  mdx:utrn	  -­‐/-­‐	   ,	  using	  non-­‐invasive	  modalities,	  PET-­‐FDG,	  DCE-­‐CT	  and	  echocardiography.	  	  My	  three	  main	  goals	  were	  to:	  1. Use	  DCE-­‐CT	  to	  measure	  longitudinal	  changes	  in	  myocardial	  perfusion	  (blood	  flow	   and	   blood	   volume)	   in	   affected	   (dystrophic)	   mice,	   relative	   to	   healthy	  wild-­‐type	  control	  mice.	  2. Use	   positron	   emission	   tomography	   (PET-­‐18FDG)	   to	   longitudinally	   measure	  changes	  in	  glucose	  metabolism	  in	  affected	  myocardia.	  3. Use	   echocardiography	   to	   compare	   the	   morphological/architectural	   and	  functional	  changes	  in	  affected	  myocardia.	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  CHAPTER	  2:	  MATERIALS	  AND	  METHODS	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2.1	  Animal	  Models	  of	  Duchenne	  Muscular	  Dystrophy	  
All	  animal	  protocols	  were	  approved	  by	  the	  Institutional	  Animals	  Ethics	  Committee,	  University	   of	  Western	  Ontario,	   and	   experiments	  were	   conducted	   in	   accordance	   to	  the	  guidelines	  of	  the	  Canadian	  Council	  of	  Animal	  Care	  (CCAC)	  (animal	  use	  protocol	  approval	   letter	   attached	   in	   appendix).	   	   Wild-­‐type	   C57BL/6	  mice	   were	   purchased	  from	  Charles	  River	  Laboratory	  International,	  Inc	  (Wilmington,	  MA)	  at	  5-­‐7	  weeks	  of	  age.	   Mdx:utrn	   heterozygote	   (+/-­‐)	   mice	   (generously	   provided	   by	   Robert	   Grange,	  Virginia	  Polytechnic	  Institute	  and	  State	  University,	  although	  originally	  generated	  by	  Mark	   Grady	   and	   Josh	   Sanes	   at	   Washington	   University,	   St.	   Louis)	   were	   bred	   to	  generate	  mdx:utrn	   -­‐/-­‐	  mice	   lacking	  both	  utrophin	  and	   functional	  dystrophin.	  Only	  males	  were	   used	   in	   the	   study.	   Two	   groups	   of	  mice	  were	   used:	   (1)	  wild-­‐type,	   (2)	  mdx:utrn	  -­‐/-­‐.	  For	  the	  CT	  and	  PET	  experiments,	  5	  mice	  were	  enrolled	  in	  each	  group	  and	  scanned	  bi-­‐weekly	  starting	  at	  5-­‐7	  weeks	  of	  age	  for	  up	  to	  16-­‐21	  weeks	  of	  age	  or	  until	  their	  death.	  	  For	  the	  echocardiography	  pilot	  study,	  2	  mice	  were	  enrolled	  in	  the	  mdx:utrn	   -­‐/-­‐	   group	   and	   5	  were	   enrolled	   in	   the	  wild-­‐type	   group.	   Each	  mouse	  was	  scanned	  at	  two	  time	  points:	  5-­‐7	  weeks	  of	  age,	  and	  15-­‐17	  weeks	  of	  age.	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2.2	  DCE-­‐CT,	  PET-­‐FDG,	  and	  Echocardiography	  	  




2.2.2	  Echocardiography	  Mice	  in	  wild-­‐type	  and	  mdx:utrn	  -­‐/-­‐	  groups	  were	  enrolled	  at	  5-­‐7	  weeks	  of	  age.	  Mice	  were	  scanned	  at	  two	  time	  points;	  (1)	  The	  first	  scan	  was	  conducted	  at	  5-­‐7	  weeks	  of	  age,	   and	   (2)	   the	   second	   scan	  was	   conducted	   at	   15-­‐17	  weeks	   of	   age.	   During	   each	  scanning	   session,	   anesthesia	   was	   performed	   with	   a	   3-­‐4%	   isoflourane	   and	   then	  maintained	  with	  a	  1.5%	  oxygen-­‐balanced	   isoflourane	  mixture,	  delivered	  at	   rate	  of	  1ml/min.	   Mice	   were	   then	   placed	   on	   a	   heated	   platform	   with	   electrocardiogram	  contact	   pads	   while	   in	   a	   supine	   position.	   Dipilatory	   cream	   was	   placed	   on	   each	  mouse’s	  chest	  and	  removed	  after	  2	  minutes	  to	  remove	  the	  hair.	  Ultrasound	  gel	  was	  subsequently	   placed	   on	   the	   chest	   of	   the	   anesthetized	   mouse	   and	   different	  parameters	   of	   the	   heart	   were	   measured	   (will	   be	   discussed	   in	   later	   sections)	   to	  assess	  cardiomyopathy	  and	  overall	  heart	  function.	  	  	  
Figure	  2.1:	  Scan	  Time	  line	  for	  CT	  and	  PET.	  Mice	  in	  two	  groups	  were	  enrolled	  at	  baseline	  (5-­‐7	  Weeks	  of	  age),	  and	  were	  imaged	  once	  every	  two	  weeks	  for	  up	  to	  21	  weeks	  of	  age.	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2.3	  DCE-­‐CT	  	  
2.3.1	  Measurement	  of	  Cardiac	  Blood	  Flow	  and	  Blood	  Volume	  Two	  parameters	  of	  perfusion	  (blood	  flow	  and	  blood	  volume)	  were	  analyzed	  in	  this	  study	  for	  each	  mouse.	  2	  cm	  thick	  slab	  (containing	  the	  heart),	  separated	  into	  sixteen	  1.25mm	  thick	   slices	  at	  320μm	  resolution	  was	   scanned	   repetitively	  using	  a	  	  Clinical	  GE	  scanner.	  The	  scan	  was	  divided	  into	  two	  phases.	  The	  first	  phase	  consisted	  of	   24	   times	   exposure	   of	   0.4	   seconds	   with	   prep	   time	   of	   1s	   followed	   by	   12	   times	  exposure	   of	   0.4	   seconds	  with	   14.6	   s	   prep	   time.	  Mice	  were	   injected	  with	   contrast	  agent	  via	   tail	  vein	  catheter	  5	  seconds	   into	   the	   first	  scan.	  Conray	  43	  contrast	  agent	  diluted	  to	  50%	  with	  sterile	  saline	  was	  injected,	  at	  0.2	  mls	  volume	  and	  2	  ml/min	  rate	  for	  mice	  weighting	  more	  than	  20g	  and	  0.15	  mls	  volume	  for	  mice	  weighting	  less	  than	  20g,	  using	  an	  infusion	  pump	  (New	  Era	  Pump	  System	  Inc)	  that	  was	  triggered	  by	  the	  CT	   scanner.	   Blood	   flow	   (BF)	   and	   blood	   volume	   (BV)	   maps	   were	   subsequently	  reconstructed	  using	   the	  GE	  CT	  perfusion	   software,	  which	   is	   based	  on	   the	   Johnson	  Wilson	  model	  with	  adiabatic	  approximation	  (9,72-­‐74).	  	  A	  tissue	  density	  value	  of	  2.5	  was	  used.	  Regions	  of	  interest	  (ROI)	  were	  placed	  in	  the	  lateral,	  inferior,	  septal	  walls	  of	  left	  myocardium	  were	  used	  to	  extract	  the	  BF	  and	  BV	  values	  (Figure	  2.2	  and	  Figure	  2.3).	  A	  ROI	  was	  not	  placed	  with	  within	  anterior	  wall	  of	  left	  myocardium	  due	  to	  high	  cardiac	  wall	  motion.	   	   Values	   of	   BF	   and	   BV	   for	   each	  mouse	  was	   normalized	   to	   its	  baseline	   in	  order	  to	  remove	  biological	  variability.	  The	  values	  from	  mice	  respective	  to	  their	  own	  group	  and	  weeks	  were	  then	  averaged.	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2.3.2	  Measuring	  cardiac	  volume	  via	  CT	  Cardiac	   volume	   was	   also	   calculated	   using	   high	   resolution	   CT	   scans	   previously	  obtained	  for	  the	  two	  mice	  groups.	  Area	  was	  measured	  using	  the	  GE	  Workstation	  (GE	  Healthcare)	  with	  use	  of	  its	  software	  (CT	  Perfusion™,	  GE	  HealthCare).	  For	  each	  scan,	  the	  slices	  containing	  the	  heart	  were	  chosen	  and,	  using	  a	  hand	  drawing	  tool,	  the	  heart	  boundary	  was	   outlined	   and	   the	   area	   containing	   the	   heart	  was	  measured.	   Cardiac	  volume	  was	  calculated	  using	  a	  slice	  thickness	  value	  of	  1.25mm	  and	  areas	  measured	  (in	  mm2).	  This	  was	  done	   for	  each	   time	  point.	  The	  values	  were	   then	  normalized	   to	  baseline	  and	  averaged	   for	  each	  of	   the	   two	  groups	  to	  measure	  potential	  changes	   in	  the	  cardiac	  volume	  for	  the	  two	  groups	  in	  time.	  	  	  
2.4	  PET-­‐FDG	  for	  measurement	  of	  glucose	  metabolism	  
In	   this	  PET	  study,	   the	   radioactive	   tracer	   18	  F-­‐FDG	  (fluorodeoxyglucose)	  was	  used	  to	  measure	  glucose	  metabolism.	  Mice	  were	  injected	  via	  tail-­‐vein	  catheter	  with	  300-­‐400	  μCi	   of	   18F-­‐FDG.	  After	   45	  min	   to	   1	   hour	   of	   uptake	   time,	   static	   scans	  were	  acquired	  using	  a	  μPET	  scanner	  (GE	  Healthcare,	  Explorer	  Vista	  DR)	  at	  a	  photopeak	  of	  250-­‐700	  keV	   for	  a	  period	  of	  30	  minutes.	   Images	  were	  subsequently	   reconstructed	  using	   3D	   Fore-­‐2D	   OSEM	   algorithm	   and	   corrected	   for	   scatter	   and	   random	  coincidences,	   into	  twenty-­‐six,	  1.75	  mm	  thick	  slices	  at	  a	  transaxial	  resolution	  of	  1.6	  mm.	  A	  5	  cm	  diameter	  water	  phantom	  containing	  a	  known	  amount	  of	  F-­‐18	  activity	  was	   scanned	   with	   μPET	   to	   measure	   the	   sensitivity	   factor.	   This	   value	   was	  subsequently	  used	  for	  converting	  counts	  in	  reconstructed	  PET	  images	  to	  activity	  (in	  MBq).	  ROIs	  were	  drawn	  in	  the	  regions	  of	  lateral,	  inferior,	  septal,	  and	  anterior	  walls	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Figure	  2.2:	  Region	  of	  analysis	  used	  for	  PET	  and	  CT.	  Areas	  represent	  lateral	  wall,	  inferior	  wall,	  septal	  wall,	  and	  anterior	  wall	  of	  the	  left	  myocardium.	  Left	  and	  right	  ventricles	  are	  also	  shown.	  For	  CT	  the	  region	  of	  anterior	  wall	  is	  avoided	  due	  to	  high	  cardiac	  wall	  motion.	  	  	  
SUV =
mean_ value / pixel
phantom_ correction_ factor
amount _of _ radioisotope_ at _ start _of _ scan(MBq)
mouse_weight(g)





Figure	  2.3:	  Sample	  DCE-­‐CT	  image.	  Left:	  blood	  flow.	  Right:	  blood	  volume.	  Axial	  slices	  using	  DCE-­‐CT	  of	  cardiac	  of	  a	  wild-­‐type	  mouse.	  White	  regions	  represent	  the	  regions	  of	  analysis,	  which	  represent	  lateral	  wall,	  inferior	  wall,	  septal	  wall	  of	  left	  myocardium.	  For	  CT,	  the	  region	  of	  anterior	  wall	  is	  avoided	  due	  to	  high	  cardiac	  wall	  motion.	  	  	  
2.5	  Echocardiography	  for	  measurement	  of	  cardiac	  
anatomy	  and	  blood	  flow	  	  All	  echocardiography	  and	  analysis	  was	  conducted	  with	  aid	  of	  Yin	  Liu	  (Dr.	  Qingping	  Feng’s	   group	   at	   the	   University	   of	   Western	   Ontario).	   Echocardiography	   was	  performed	   using	   a	   Vevo	   2100	   High	   Frequency	   Ultrasound	   scanner	   (Visual	   Sonics	  Inc.,	   Toronto,	   Canada).	   The	   ultrasound	   probe	   used	  was	  MS-­‐550D,	   operating	   at	   40	  MHz	   with	   an	   axial	   resolution	   and	   lateral	   resolution	   of	   40	   μm	   and	   80	   μm,	  respectively.	  Images	  were	  obtained	  according	  to	  echocardiography	  guidelines	  using	  M-­‐mode	   and	   B-­‐Mode.	   Quantitative	   measurements	   were	   performed	   using	   the	  integrated	   analytical	   software	   of	   the	   scanner.	   The	   following	   parameters	   were	  measured:	  (1)	  left	  ventricular	  internal	  diameter	  (LVID)	  at	  both	  systole	  and	  diastole,	  
	  	  
26	  
(2)	  anterior	  and	  septal	   (posterior)	  wall	   thickness	  at	  both	  systole	  and	  Diastole,	   (3)	  ejection	  fraction	  (EF)	  and	  (4)	  shortening	  fraction	  (SF)	  (Figure	  2.4).	  Ejection	  fraction	  is	   the	   volumetric	   fraction	   of	   blood	   that	   is	   pumped	   out	   of	   the	   left	   ventricle	   during	  each	  beat,	  and	  is	  defined	  as	  (LV	  diastolic	  volume	  –LV	  systolic	  volume)/	  LV	  diastolic	  volume.	   	   Shortening	   fraction	   is	   the	  measurement	  of	   the	   change	   in	   the	  diameter	  of	  left	  ventricle	  and	  is	  defined	  as	  (LVID	  (at	  diastole)-­‐LVID	  (at	  Systole))/LVID	  (at	  diastole).	  Both	  EF	  and	  SF	  were	  used	  for	  assessment	  of	  ventricular	  performance.	  	  
	  




2.6	  Histological	  Analyses	  
Histology	  was	  performed	  at	  two	  time	  points:	  (1)	  baseline	  and	  (2)	  at	  the	  termination	  of	  the	  study.	  	  Three	  mdx:utrn	  -­‐/-­‐	  mice	  at	  end	  point,	  2	  mdx:utrn	  -­‐/-­‐	  mice	  at	  baseline,	  and	   	   3	   wild-­‐type	   mice	   for	   both	   time	   points	   were	   used.	   Immediately	   following	  euthanasia,	  hearts	  were	  removed	  and	  placed	  in	  10%	  formalin	  for	  a	  minimum	  of	  48	  hours.	  Fixed	  hearts	  were	  then	  cut	  in	  2	  or	  3	  axial	  sections	  (depending	  on	  heart	  size)	  then	  were	  embedded	  in	  paraffin.	  Five	  mm-­‐thick	  sections	  were	  subsequently	  cut	  and	  sent	   to	   the	   Molecular	   Pathology	   Core	   Facility	   at	   the	   Robarts	   Research	   Institute	  	  (RRI)	   (London,	   Canada)	   to	   be	   stained	   with	   Hematoxylin	   and	   eosin	   (H&E)	   and	  Masson’s	   trichrome	   staining.	  H&E	   staining	  was	   used	   to	   quantify	   hypertrophy	   and	  Masson’s	   Trichrome	   staining	  was	   used	   to	   quantify	   fibrosis	   as	   previously	   done	   by	  Xiang	  et	  al.	  (2009)	  and	  Gao	  et	  al.	  (2003)	  (83,84).	  	  
2.6.1	  Quantifying	  Fibrosis	  Quantifying	  fibrosis	  was	  conducted	  in	  trichrome	  stained	  heart	  sections	  using	  Zeiss	  Axioskop,	   and	  Northern	   Eclipse	   Software	   (V7.0,	   Empix	   Imaging	   Inc.).	   Using	   a	   40X	  magnification	  power,	  3	  sub-­‐region	  snapshot	  images	  were	  obtained	  from	  each	  region	  of	  lateral	  wall,	   inferior	  wall,	  septal	  wall,	  and	  anterior	  walls	  of	  the	  left	  myocardium.	  	  Using	  ImageJ	  (Version1.45I)	  software,	  areas	  encompassing	  the	  fibrosis	  regions	  were	  outlined	   and	  measured,	   and	   the	   ratio	  of	   total	   fibrosis	   area	  over	   total	   area	  of	   each	  sub-­‐region	   was	   calculated.	   The	   ratio	   of	   fibrosis	   for	   each	   of	   the	   4	   regions	   of	   the	  myocardial	   wall	   was	   calculated	   by	   averaging	   the	   ratio	   of	   in	   corresponding	   sub-­‐
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regions.	  Overall	  fibrosis	  ratio	  was	  calculated	  by	  averaging	  the	  ratio	  of	  fibrosis	  of	  the	  4	  regions	  (83,84).	  
2.6.2	  Quantifying	  cell	  size	  	  Hypertrophy	  in	  the	  H&E	  stained	  sections	  was	  also	  quantified	  using	  a	  Zeiss	  Axioskop,	  and	  Northern	  Eclipse	  Software	  (V7.0,	  Empix	  Imaging	  Inc).	  Using	  a	  40X	  magnification	  power,	  3	  sub-­‐region	  snapshot	  images	  were	  obtained	  from	  each	  region	  of	  the	  lateral	  wall,	   inferior	   wall,	   septal	   wall,	   and	   anterior	   walls	   of	   the	   left	   myocardium.	   	   Using	  ImageJ	   (Version1.45I)	   software,	   the	   short	   axis	   length	   of	   20	   cardiomyocytes	   was	  measured	   in	   each	   sub-­‐region	   and	   averaged	   (cell’s	   short	   axis	   length	   was	   used	   for	  quantification	   of	   cell	   size).	   Assessment	   of	   hypertrophy	   in	   each	   region	   of	   the	   left	  myocardium	   was	   done	   through	   averaging	   the	   cell	   size	   measurements	   for	   its	  corresponding	  region.	  These	  values	  were	  then	  averaged.	  
2.7	  Data	  Analysis	  
All	  statistics	  were	  performed	  with	  the	  aid	  and	  guidance	  of	  Dr.	  Yves	  Bureau	  (Lawson	  Health	  Research	  Institute).	  Statistical	  analyses	  were	  performed	  using	  SPSS	  software	  package	   for	  Mac	  (SPSS	   Inc,	  V20.0),	  and	  Graphpad	  Prism	  software	  package	   for	  Mac	  (Graphpad	   Software	   Inc,	   V5.0a).	   To	   identify	   significance	   difference	   in	   BF,	   BV,	   and	  SUV	  parameters	  within	  the	  2	  groups	  of	  mice	  over	  time,	  and	  between	  the	  two	  groups	  of	   mice	   over	   time,	   a	   repeated	   measures	   two-­‐way	   ANOVA	   (mixed-­‐model)	   with	  Bonferroni	   post-­‐test	  was	  performed.	   Significance	  differences	   in	   the	   two	   groups	   of	  mice	  at	  end	  point	  of	  histology	  were	  measured	  using	  an	  unpaired	  t-­‐test.	  Low	  sample	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size	  of	  mdx:utrn	  -­‐/-­‐	   in	  echocardiography	  and	  baseline	  of	  histology	  prevented	  from	  inferring	  statistical	  analysis.	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  CHAPTER	  3:	  RESULTS	  	  	  	  	  	  	  	  	  	  
3.1	  A	  Kaplan	  Meier	  survival	  curve	  demonstrates	  that	  the	  
lifespan	  of	  mdx:utrn	  -­‐/-­‐	  mice	  is	  significantly	  shorter	  than	  
wild-­‐type	  mice	  	  
	  Figure	  3.1:	  Kaplan-­‐Meier	  survival	  curve	  of	  wild-­‐type	  and	  mdx:utrn	  -­‐/-­‐	  mice.	  Mice	  that	  were	  sacrificed	  at	  specific	  histological	  time	  points	  were	  not	  included	  in	  the	  Kaplan-­‐Meier	  survival	  curve.	  Data	  was	  collected	  over	  2	  year	  period.	  n=18	  for	  wild-­‐type	  and	  n=62	  for	  mdx:utrn	  -­‐/-­‐	  mice	  were	  used.	  Y-­‐axis	  depicts	  the	  fraction	  of	  survival	  with	  a	  value	  of	  1	  depicting	  100%	  survival.	  The	  x-­‐axis	  depicts	  the	  age	  of	  the	  mice	  in	  weeks.	  LOG	  Rank	  (Mantel-­‐Cox)	  statistical	  test	  found	  significant	  difference	  between	  the	  two	  groups	  (P<0.0001)	  	  




3.2	  Dynamic	  contrast	  enhanced	  computed	  tomography	  
(DCE-­‐CT)	  demonstrates	  that	  myocardial	  perfusion	  is	  not	  
affected	  in	  the	  mdx:utrn-­‐/-­‐	  mice	  relative	  to	  healthy	  wild-­‐
type	  mice.	  	  
	  





Figure	  3.2b:	  Normalized	  blood	  volume	  analysis	  in	  the	  left	  ventricular	  myocardium	  of	  wild-­‐type	  and	  mdx:utrn	  -­‐/-­‐	  mice.	  	  Data	  was	  collected	  over	  a	  10	  weeks	  period	  and	  mice	  were	  enrolled	  in	  study	  at	  5-­‐7	  weeks	  of	  age	  (baseline	  scan	  (w0)).	  Repeated	  measures	  two-­‐way	  Anova	  (mixed-­‐model)	  with	  Bonferroni	  post-­‐test	  showed	  no	  significance	  in-­‐between	  and	  within	  the	  groups.	  Each	  value	  represents	  the	  mean	  of	  the	  normalized	  blood	  volume	  values	  for	  each	  group	  at	  each	  time	  point.	  Error	  bars	  represent	  the	  standard	  error	  of	  the	  mean	  for	  each	  group	  at	  each	  time	  point.	  	  	  	   Given	  reports	  of	   longitudinal	  change	  in	  the	  blood	  flow	  and	  blood	  volume	  in	  the	   skeletal	  muscle	   of	  mdx:utrn-­‐/-­‐	  mice	   vs	  wild-­‐type	  mice	   (Ahmad	   et	   al.	   2011),	   I	  sought	  to	  assess	  changes	  in	  the	  ventricular	  myocardium	  perfusion	  (BF	  and	  BV).	  As	  illustrated	  in	  Figure	  3.2	  a	  there	  is	  no	  significant	  difference	  between	  the	  healthy	  wild-­‐type	   mice	   and	   the	   mdx:utrn-­‐/-­‐	   mice	   at	   baseline	   (W0),	   or	   over	   a	   10	   weeks	   time	  period.	  Blood	  flow	  was	  similarly	  unaffected	  (Figure	  3.2b).	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3.3	  Cardiac	  Volume	  is	  also	  unaffected	  in	  mdx:utrn	  -­‐/-­‐	  mice	  
as	  assessed	  by	  DCE-­‐CT	  	  
	  




3.4	  Positron	  Emission	  tomography	  (PET-­‐FDG)	  
demonstrates	  that	  glucose	  metabolism	  is	  unaffected	  in	  the	  
mdx:utrn-­‐/-­‐	  mice	  relative	  to	  healthy	  wild-­‐type	  mice.	  
	  
Figure	  3.4:	  Normalized	  standard	  uptake	  value	  (SUV)	  of	  PET-­‐FDG	  in	  left	  ventricular	  myocardium	  of	  wild-­‐type	  and	  mdx:utrn	  -­‐/-­‐	  mice.	  Data	  was	  collected	  over	  a	  10	  weeks	  period	  and	  mice	  were	  enrolled	  in	  study	  at	  5-­‐7	  weeks	  of	  age	  (baseline	  scan	  (w0)).	  Repeated	  measures	  two-­‐way	  Anova	  (mixed-­‐model)	  with	  Bonferroni	  post-­‐test	  showed	  no	  significance	  in-­‐between	  and	  within	  the	  groups.	  Each	  value	  represents	  the	  mean	  of	  the	  normalized	  SUV	  values	  for	  each	  group	  at	  each	  time	  point.	  Error	  bars	  represent	  the	  standard	  error	  of	  the	  mean	  for	  each	  group	  at	  each	  time	  point.	  	  Given	  reports	  of	  longitudinal	  change	  in	  the	  glucose	  uptake	  in	  the	  skeletal	  muscle	  of	  mdx:utrn-­‐/-­‐	  mice	  vs.	  wild-­‐type	  mice	  (Ahmad	  et	  al.	  2011),	  I	  sought	  to	  assess	  changes	  in	  the	  ventricular	  myocardium	  glucose	  uptake	  .	  As	  illustrated	  in	  Figure	  3.4	  there	  was	  no	  significant	  difference	  between	  the	  healthy	  wild-­‐type	  mice	  and	  the	  mdx:utrn-­‐/-­‐	  mice	  at	  baseline	  (W0),	  or	  over	  a	  10	  weeks	  time	  period.	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3.5	  Pilot	  Echocardiography	  shows	  decrease	  in	  the	  cardiac	  
function	  of	  mdx:utrn-­‐/-­‐	  mice	  compared	  to	  healthy	  wild-­‐
type	  mice.	  	  
Table	  1.	  Echocardiograph	  data	  for	  mdx:utrn-­‐/-­‐	  and	  wild-­‐type	  mice	  at	  5-­‐7	  (baseline),	  and	  15-­‐17	  weeks	  of	  age	  (endpoint).	  N=5,	  and	  n=2	  was	  used	  for	  wild-­‐type	  and	  mdx:utrn-­‐/-­‐	  mice	  respectively.	  	  	  
LVID'd:	  Left	  ventricular	  internal	  diameter	  (diastole),	  LVID's:	  Left	  ventricular	  internal	  diameter	  (systole),	  Ad:	  Anterior	  wall	  thickness	  (Diastole),	  As:	  Anterior	  wall	  thickness	  (sytole),	  Pd:	  Septal	  (posterior)	  wall	  thickness	  (diastole).	  Ps:	  Septal	  (posterior)	  wall	  thickness	  (systole),	  EF:	  Ejection	  Fraction,	  FS:	  Fractional	  Shortening	  
	  









LVID'd(mm)	   3.7294	   3.369	   3.1252	   2.981	  
LVID's(mm)	   2.41336	   2.35	   1.8992	   2.559	  
Ad(mm)	   0.9364	   0.883	   0.7884	   0.694	  
As(mm)	   1.2852	   1.2545	   1.1432	   0.844	  
Pd(mm)	   0.7514	   0.9605	   0.7786	   0.939	  
Ps(mm)	   1.1596	   1.3675	   1.0726	   1.048	  
EF(%)	   62.5492	   58.5815	   72.1582	   31.3575	  










Figure	  3.5:	  Echocardiograph	  trend	  data	  for	  mdx:utrn-­‐/-­‐	  and	  wild-­‐type	  mice	  at	  5-­‐7	  (baseline),	  and	  15-­‐17	  weeks	  of	  age	  (endpoint).	  N=5,	  and	  n=2	  was	  used	  for	  wild-­‐type	  and	  mdx:utrn-­‐/-­‐	  mice	  respectively.	  A)	  Left	  ventricular	  internal	  diameter	  at	  diastole.	  B)	  Left	  ventricular	  internal	  diameter	  at	  systole.	  C)	  Anterior	  wall	  thickness	  at	  diastole.	  D)	  Anterior	  wall	  thickness	  at	  systole.	  E)	  Posterior	  (septal)	  wall	  thickness	  at	  diastole.	  F)	  Posterior	  (septal)	  wall	  thickness	  at	  systole.	  G)	  Ejection	  fraction.	  H)	  Fractional	  shortening	  	  	  	   Echocardiography	  parameters	  measurements	  are	  of	   left	  ventricular	  internal	  diameter	   (LVID)	   at	   systole	   and	   diastole,	   anterior	   and	   septal	   (posterior)	   wall	  thickness	   at	   systole	   and	   diastole,	   ejection	   fraction	   (EF)	   and	   fractional	   shortening	  (FS)	  for	  the	  two	  groups	  of	  mdx:utrn	  -­‐/-­‐	  and	  wild-­‐type	  mice	  at	  two	  time	  points	  of	  5-­‐7	  weeks	  of	  age	  (baseline)	  and	  15-­‐17	  weeks	  of	  age	  (endpoint)	  are	  depicted	  in	  table	  1	  and	  Figure	  3.5.	  Low	  sample	  size	   in	  our	  mdx:utrn	   -­‐/-­‐	  group	  prevented	   inference	  of	  statistical	   relevance.	   Overall,	   I	   observed	   an	   increasing	   trend	   in	   left	   ventricular	  internal	  diameter	  at	  systole	  from	  the	  first	  time	  points	  of	  5-­‐7	  weeks	  of	  age	  (baseline)	  to	  second	  time	  point	  of	  15-­‐17	  weeks	  of	  age	  (end-­‐point	  of	  study),	  whereas	  decreasing	  trend	  was	  observed	  in	  the	  wild-­‐type	  mice	  (Figure	  3.5B).	  FS	  and	  EF	  were	  observed	  to	  have	   increasing	   trend	   in	   the	   wild-­‐type	   mice,	   however	   decreasing	   trend	   were	  observed	   in	   these	   two	   echocardiography	   parameters	   in	   mdx:utrn-­‐/-­‐	   mice	   from	  baseline	  to	  end-­‐point	  of	  study	  (Figure	  3.5	  G&H).	  	  




3.6.1	  Fibrosis	  quantification	  shows	  significantly	  higher	  fibrosis	  in	  the	  
left	  myocardium	  mdx:utrn-­‐/-­‐	  mice	  vs.	  healthy	  wild-­‐type	  mice	  at	  
termination	  of	  study.	  
	  
	  
Figure	  3.6:	  Cardiac	  Fibrosis	  Quantification.	  Baseline	  (n=2	  for	  mdx:utrn-­‐/-­‐	  and	  n=3	  for	  wild-­‐type).	  Endpoint	  (n=3	  for	  mdx:utrn-­‐/-­‐	  and	  n=3	  for	  the	  wild-­‐type)	  A)	  Quantification	  of	  cardiac	  fibrosis	  in	  mdx:utrn	  -­‐/-­‐	  and	  wild-­‐type	  mice	  sacrificed	  at	  baseline.	  Low	  sample	  size	  in	  our	  mdx:utrn	  -­‐/-­‐	  group	  prevented	  inference	  of	  statistical	  relevance	  B)	  Trichrome	  stained	  images	  of	  the	  left	  myocardium	  of	  wild-­‐type	  mouse	  (taken	  at	  baseline)	  under	  40X	  magnification.	  C)	  Trichrome	  stained	  images	  of	  the	  left	  myocardium	  of	  mdx:utrn-­‐/-­‐	  mouse	  (taken	  at	  baseline)	  under	  40X	  magnification.	  Yellow	  arrow	  tips	  point	  to	  areas	  of	  fibrosis.	  D)	  Quantification	  of	  cardiac	  fibrosis	  in	  mdx:utrn	  -­‐/-­‐	  and	  wild-­‐type	  mice	  sacrificed	  at	  end	  of	  study	  (endpoint).	  Unpaired	  T-­‐test	  shows	  significantly	  higher	  fibrosis	  in	  the	  mdx:utrn	  -­‐/-­‐	  mice	  compared	  to	  healthy	  wild-­‐type	  mice	  (P<0.05).	  E)	  Trichrome	  stained	  images	  of	  the	  left	  myocardium	  of	  wild-­‐type	  mouse	  (taken	  at	  endpoint)	  under	  40X	  magnification.	  Yellow	  arrow	  tips	  point	  to	  areas	  of	  fibrosis.	  F)	  Trichrome	  stained	  images	  of	  the	  left	  myocardium	  of	  mdx:utrn-­‐/-­‐	  mouse	  (taken	  at	  endpoint)	  under	  40X	  magnification.	  Yellow	  arrow	  tips	  depicts	  areas	  of	  fibrosis.	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3.6.2	  Cell	  size	  measurement	  (Hypertrophy	  assessment)	  shows	  
significantly	  increased	  cell	  size	  at	  endpoint	  of	  study	  	  
	  
Figure	  3.7:	  cardiomyocyte	  size	  (cell	  size)	  quantification	  to	  assess	  




	  Quantification	  of	  cardiac	  fibrosis	  were	  conducted	  at	  two	  time	  points	  of	  baseline	  and	  at	   the	   end	   of	   the	   study	   (Figure	   3.6).	   Significantly	   higher	   cardiac	   fibrosis	   was	  observed	  in	  mdx:utrn-­‐/-­‐	  mice	  group	  at	  termination	  of	  study	  (9.4%	  cardiac	  fibrosis)	  	  when	  compared	  to	  wild-­‐type	  mice	  (1.7%	  cardiac	  fibrosis)(P=0.0388).	  Quantification	  of	  cardiomyocytes	  size	  (cardiomyocytes	  hypertrophy	  assessment)	  were	  conducted	  at	  the	  two	  time	  points	  of	  baseline	  and	  end	  of	  study	  (Figure	  3.7).	  Significantly	  higher	  cardiomyocyte	  size	  was	  observed	   in	  mdx:utrn	   -­‐/-­‐	  mice	  group	  (average	  of	  34μm	  at	  end	  point)	  when	  compared	  to	  age	  matched	  wild-­‐type	  mice	  (average	  of	  31μm)	  at	  end	  point	  (P=0.0328).	   	  Low	  sample	  size	  in	  our	  mdx:utrn	  -­‐/-­‐	  group	  prevented	  inference	  of	  statistical	  relevance	  at	  baseline	  for	  fibrosis	  and	  cell	  size	  quantification.	  	  	  	  	  	  	  	  	  	  	  	  
	  	  
41	  CHAPTER	  4:	  DISCUSSION/CONCLUSION/LIMITATIONS/FUTURE	  DIRECTIONS	  
4.0	  Discussion	  
Duchenne	   muscular	   dystrophy	   (DMD)	   is	   an	   X-­‐linked	   recessive	  neuromuscular	  disease	  that	  results	  from	  a	  loss	  of	  functional	  dystrophin,	   leading	  to	  cardiomyocyte	   death,	   fibrosis,	   and	   dilated	   cardiomyopathy.	   In	   this	   thesis,	   I	   have	  utilized	   dynamic	   contrast	   enhanced	   computed	   tomography	   (DCE-­‐CT),	   positron	  emission	   tomography	   (PET-­‐FDG),	   echocardiography,	   and	   traditional	   histology	   to	  longitudinally	  assess	  disease	  progression	  and	  degree	  of	  cardiomyopathy	  in	  a	  murine	  model	  of	  DMD	  (mdx:utrn	   -­‐/-­‐	  mice)	  and	  compared	   these	  results	   to	  a	  control	  group	  (wild-­‐type	  mice).	  	  Use	   of	   DCE-­‐CT,	   PET-­‐FDG,	   and	   echocardiography	   each	   have	   distinct	  advantages	  and	  drawbacks	  to	  their	  use.	  One	  of	  the	  main	  advantages	  of	  functional	  CT	  over	  other	  modalities	  has	  been	  its	  simplicity	  and	  accessibility	  to	  patients.	  However,	  one	  of	  the	  drawbacks	  of	  CT	  is	  the	  high	  dose	  of	  radiation	  delivered	  to	  the	  body(71).	  	  Previously,	   PET	   has	   been	   used	   as	   the	   gold	   standard	   to	   validate	   new	   imaging	  techniques	  (ex.	  MRI)	   (85-­‐89).	  Advantages	  of	  using	  PET	   include	   its	  high	  sensitivity,	  and	  it	  usefulness	  to	  illustrate	  organ	  functionality.	  However,	  the	  disadvantage	  of	  PET	  is	  exposure	  to	   ionizing	  radiation.	  Echocardiography	  benefits	   include	  low	  operating	  cost,	   lack	   of	   ionizing	   radiation,	   short	   scan	   times,	   and	   the	   ability	   for	   images	   to	   be	  captured	   in	   real	   time.	   One	   of	   the	   drawbacks	   of	   the	   diagnostic	   ultrasound	   is	   its	  operator	  dependence	  (operational	  variability	  that	  is	  introduced	  by	  the	  operator).	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Given	   reports	   by	  Perloff	   et	   al.	   (1984)	   and	  Quinlivan	   et	   al.	   (1996),	   in	  which	  they	   assessed	  myocardial	   perfusion	   and	  metabolism	   in	   DMD	   patients	   (18,44),	  we	  sought	  to	  assess	  these	  parameters	  in	  dystrophic	  mice	  using	  DCE-­‐CT,	  and	  PET-­‐FDG.	  Despite	   observing	   a	   significant	   difference	   in	   the	   survival	   fraction	   of	   mdx:utrn-­‐/-­‐,	  relative	   to	   healthy	  mice,	   I	   did	   not	   observe	   	   significant	   changes	   in	   the	  myocardial	  blood	  flow,	  	  and	  blood	  volume	  as	  measured	  	  via	  DCE-­‐CT	  (Figure	  3.2	  a,b).	  	  Standard	  uptake	   value	   of	   glucose	   (ie.	   metabolism)	   in	   the	   left	   myocardium	   was	   similarly	  unaffected	   over	   time	   (Figure	   3.4).	   Furthermore,	   I	   did	   not	   observe	   significant	  difference	  in	  the	  CT-­‐measured	  cardiac	  volume	  over	  time.	  Surprisingly,	  these	  results	  are	  not	  in	  parallel	  with	  previous	  cardiac	  studies	  that	  utilized	  PET	  to	  assess	  perfusion	  and	  metabolism	  in	  human	  DMD	  patients.	  Specifically,	  using	  PET-­‐FDG	  and	  PET-­‐NH3,	  Perloff	   et	   al.	   (1984)	   measured	   metabolism	   and	   perfusion	   in	   the	   left	   ventricular	  myocardium	  of	  DMD	  patients.	  They	  found,	  that	  in	  11	  out	  of	  12	  patients	  there	  was	  an	  increase	  in	  glucose	  utilization	  in	  the	  areas	  of	  posteriobasal	  and	  posteriolateral	  walls	  of	  the	  left	  ventricle.	  Perloff	  et	  al.	  (1984)	  further	  demonstrated	  that	  in	  13	  out	  of	  the	  15	  DMD	  patients	  there	  was	  a	  reduction	  in	  13NH3	  activity.	  Thus,	  they	  suggested	  that	  this	   increase	   in	   glucose	   uptake	   may	   be	   due	   to	   a	   segmental	   alteration	   in	   the	  permeability	   of	   the	   membrane	   in	   addition	   to	   a	   possible	   increase	   in	   glycolysis	   of	  glucose	   in	   response	   to	   decrease	   in	   utilization	   of	   fatty	   acids	   by	   the	   myocardium.	  Decrease	  in	  the	  13N	  activity	  in	  the	  myocardium	  is	  speculated	  to	  be	  possibly	  due	  to	  a	  metabolic	  abnormality,	  which	  causes	  reduction	  in	  the	  trapping	  or	  regional	  decrease	  in	  blood	  flow	  (18).	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Radioactive	  PET	   tracers	  of	  FDG	  and	  NH3	  have	  been	  used	   in	  a	   similar	   study	  conducted	  by	  Quinlivan	   et	   al	   (1996).	   The	   authors	   demonstrate	   regional	   perfusion	  and	  metabolic	  defects	  in	  the	  left	  ventricular	  myocardium	  (in	  regions	  of	  lateral,	  apex,	  and	   anterior	   wall)	   in	   15	   out	   of	   31	   patients	   scanned.	   Out	   of	   the	   15	   patients,	   11	  exhibited	  regional	  defects	  in	  perfusion	  in	  the	  lateral	  wall	  of	  the	  left	  ventricle	  (out	  of	  these	   11	   patients,	   9	   showed	   a	   decrease	   in	   perfusion	   and	   increase	   in	   glucose	  metabolism,	   whereas	   3	   showed	   a	   decrease	   in	   both	   perfusion	   and	   metabolism).	  These	   findings	   led	   this	   group	   of	   researchers,	   to	   speculate	   that	   a	   decrease	   in	   both	  perfusion	  and	  glucose	  metabolism	  may	  be	  a	  sign	  of	  infarcted	  myocardium,	  whereas	  an	  increase	  in	  glucose	  metabolism	  in	  conjunction	  with	  decrease	  in	  blood	  flow	  may	  be	  due	  to	  ischemia	  of	  the	  myocardium	  (44).	  The	   absence	   of	   dystrophin	   appears	   to	   have	   different	   effects	   on	   the	  myocardium	   than	   on	   skeletal	   muscle	   in	   murine	   models	   of	   DMD.	   Earlier	   studies	  conducted	  in	  our	  laboratory	  by	  Ahmad	  et	  al.	  (2011)	  utilized	  DCE-­‐CT,	  and	  PET-­‐FDG	  to	  study	  perfusion	  and	  metabolism	  respectively	  in	  the	  skeletal	  muscle	  of	  mdx	  mice,	  and	  severely	  effected	  mdx:utrn-­‐/-­‐	  mice.	   Initial	  observations	  showed	  an	  increase	   in	  perfusion	   (in	   both	   blood	   flow	   and	   blood	   volume)	   and	   glucose	  metabolism	   in	   the	  early	  stage	  of	  disease.	  A	  subsequent	  decrease	  in	  both	  parameters	  characterized	  by	  later	   stages	   of	   the	   disease	   is	   mostly	   evident	   in	   mdx:utrn	   -­‐/-­‐	   mice	   (in	   mdx	   mice,	  presence	   of	   utrophin	   compensates	   for	   the	   lack	   of	   dystrophin	   leading	   to	   a	   weak	  phenotype).	   The	   authors	   suggest	   that	   the	   initial	   increase	   could	   be	   due	   to	   a	  regeneration/degeneration	   cycle	   as	   apparent	   by	   the	   centrally	   located	   nuclei,	   a	  hallmark	   of	   regeneration.	   This	   peak	   of	   glucose	   metabolism	   alongside	   enhanced	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perfusion	  was	   not	   observed	   in	  my	  myocardial	   study.	   Ahmad	   et	   al.	   (2011)	   further	  suggests,	  that	  the	  later	  decrease	  in	  perfusion	  and	  glucose	  metabolism	  may	  be	  due	  to	  necrosis	  and	  fibrosis	  (9).	  Differences	  between	  my	  findings	  and	  earlier	  studies	  assessing	  perfusion	  and	  metabolism	  in	  DMD	  patients	  may	  reflect	  differences	  between	  humans	  and	  dystrophic	  mice.	  Furthermore,	  there	  may	  be	  a	  difference	  in	  utilization	  of	  various	  imaging	  metabolites	  when	  used	  to	  assess	  myocardial	  perfusion.	  In	  addition,	  at	  the	  time	  of	  earlier	  studies	  in	  DMD	  patients,	  cardiomyopathy	  might	  have	  been	  more	  severe	  than	  what	  is	  achieved	  in	  our	  mdx:utrn	  -­‐/-­‐	  	  mouse	  model.	  This	  is	  due	  to	  vast	  improvements	  in	  the	  palliative	  care,	  particularly	  in	  use	  of	  ventilatory	  support	  for	  DMD	  patients,	  which	  have	  increased	  their	  life	  expectancy.	  	  	  As	   PET-­‐FDG	   is	   the	   gold	   standard	   for	   assessing	   cardiac	   viability	   (90-­‐93),	   it	  was	  not	  particularly	   surprising	   that	  we	  did	  not	  observe	   significant	   changes	   in	   the	  myocardial	   glucose	   uptake	   over	   time	   in	   the	   two	   groups	   of	   mice.	   Even	   though	  decreased	   cardiac	   function	   and	   fibrosis	   is	   present	   in	   midx:utrn	   -­‐/-­‐	   mice	   (shown	  through	  echocardiography	  and	  histology),	  the	  heart	  	  is	  still	  viable.	  	  In	   a	   pilot	   study,	   I	   also	   sought	   to	   validate	   the	   use	   of	   echocardiography	   to	  assess	   the	   morphological/architectural	   and	   functional	   changes	   in	   dystrophic	  myocardia.	   Low	   sample	   size	   in	   our	   mdx:utrn	   -­‐/-­‐	   group	   prevented	   inference	   of	  statistical	  relevance.	  Overall,	  increasing	  trend	  in	  left	  ventricular	  internal	  diameter	  at	  systole	  was	  observed	  in	  mdx:utrn	  -­‐/-­‐	  	  mice	  from	  5-­‐7	  weeks	  of	  age	  (baseline)	  to	  15-­‐17	   weeks	   of	   age	   (end-­‐point	   of	   study),	   compared	   to	   wild-­‐type	   mice	   (where	  decreasing	   trend	   was	   observed).	   Furthermore,	   fractional	   shortening	   and	   ejection	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fraction	   were	   observed	   to	   have	   an	   increasing	   trend	   in	   the	   wild-­‐type	   mice.	   In	  contrast,	   a	   decreasing	   trend	   was	   observed	   in	   these	   two	   echocardiography	  parameters	  in	  mdx:utrn-­‐/-­‐	  mice	  from	  baseline	  to	  the	  end-­‐point	  of	  my	  study.	  	  Ejection	  fraction	  represents	  the	  volumetric	  fraction	  of	  blood	  that	  is	  pumped	  out	   of	   the	   heart	   in	   a	   cardiac	   cycle.	   A	   decrease	   in	   its	   value	   would	   indicate,	   that	  following	   each	   cardiac	   cycle,	   there	   is	   more	   volume	   of	   blood	   that	   is	   left	   in	   the	  ventricle	   following	   diastole,	   and	   hence	   can	   be	   translated	   to	   decreased	   function	   of	  the	  heart.	   In	  humans,	  ejection	   fraction	  ranges	   from	  55%-­‐77%	  (94);	   this	   is	  a	  range	  that	   was	   also	   observed	   in	   our	   wild-­‐type	   mice	   (62%	   at	   baseline	   and	   72%	   at	   end	  point)	  (Table	  1).	  This	  was	  observed	  to	  be	  lower	  in	  the	  mdx:utrn	  -­‐/-­‐	  mice	  	  at	  15-­‐17	  weeks	  of	  age	  (31%),	  possibly	  reflecting	  decreased	  function	  of	  the	  heart	  (94).	  	  Fractional	   shortening	   is	   a	   slightly	   different	   way	   of	   measuring	   cardiac	  performance	  and	  represents	  the	  change	   in	  the	  functional	  diameter	  of	   the	  ventricle	  following	   cardiac	   cycle.	   	   A	   decrease	   in	   fractional	   shortening	  would	  mean	   that	   the	  rate	   of	   change	   of	   ventricular	   diameter	   is	   decreased,	   which	   is	   also	   translated	   to	  decreased	   cardiac	   function.	   In	   humans,	   fractional	   shortening	   ranges	   from	   30%	   to	  42%	   (95,96),	   with	   26%	   to	   30%	   representing	   decreased	   cardiac	   function	   (95,96);	  this	   is	  a	  range	  that	  was	  also	  observed	   in	  our	  wild-­‐type	  mice	  (30%	  at	  baseline	  and	  40%	  at	  endpoint)	  (95,96)	  (Table	  1).	  However,	   it	  was	  observed	  that	   this	  value	  was	  lower	   in	   mdx:utrn-­‐/-­‐	   mice	   at	   15-­‐17	   weeks	   of	   age(14%),	   possibly	   reflecting	  decreased	  function	  of	  the	  heart.	  My	   findings	   support	   a	   very	   recent	   study	   involving	   mdx:utrn-­‐/-­‐	   mice	  conducted	   by	   Chun	   et	   al.	   (2012),	   where	   they	   utilized	   echocardiography	   and	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histological	   analysis	   to	   study	   cardiac	   pathology	   and	   dysfunction	   during	  development	   of	   dilated	   cardiomyopathy	   in	   mdx:utrn	   -­‐/-­‐	   vs.	   wild-­‐type	   mice.	  Echocardiography	   data	   did	   not	   show	   salient	   differences	   between	   the	   two	   mouse	  models	  by	  5	  weeks	  of	  age.	  However,	  they	  found	  dilation	  of	  the	  left	  ventricle,	  increase	  in	   the	   end	   systolic	   and	   diastolic	   volume,	   increase	   in	   left	   ventricular	   internal	  diameter	   and	   thinning	   of	   posterior	   ventricular	   wall	   by	   15	   weeks	   of	   age.	  Furthermore	   decreased	   ejection	   fraction	   and	   fractional	   shortening	   in	   the	   left	  ventricle	  was	  also	  observed	  (63).	  	  	   Similarly,	  other	  echocardiography	  studies	  conducted	  by	  Spurney	  et	  al.	  (2008)	  and	   Quinlan	   et	   al.	   (2004)	   on	   mdx	   and	   healthy	   wild-­‐type	   mice	   have	   found	   no	  significant	   changes	   in	   cardiac	   functional	   parameters	   in	   the	   first	   2-­‐3	   months.	  However,	  a	  decrease	   in	  cardiac	   function	  was	  observed	   in	  mdx	  mice	  starting	  at	  7-­‐9	  months	   of	   age.	   They	   both	   observed	   significant	   decrease	   in	   ejection	   fraction	   and	  fractional	   shortening	   by	   7-­‐9	   month	   of	   age.	   	   Furthermore,	   Spurney	   et	   al.	   (2008),	  observed	   an	   increase	   in	   the	   left	   ventricular	   internal	   diameter	   at	   systole,	   and	   a	  decrease	   in	   left	  ventricular	  posterior	  wall	   thickness	  at	   systole.	  When	  compared	   to	  healthy	   wild-­‐type	   mice,	   mdx	   mice	   showed	   decreased	   diastolic	   and	   mean	   blood	  pressure	   (97).	   In	   addition	   to	   a	   decrease	   in	   ejection	   fraction	   and	   fractional	  shortening,	  Quinlan	  et	  al.	  (2004)	  also	  observed	  a	  greater	  LV	  mass	  in	  the	  mdx	  mice	  by	   the	   age	   of	   29	  weeks.	   Furthermore,	   dilated	   cardiomyopathy	  was	   evident	   by	   42	  weeks	  of	  age	  in	  the	  mdx	  mice	  (32).	  	  There	   are	   similarities	   in	   echocardiographic	   findings	   between	   the	   human	  DMD	  condition	  and	  mouse	  models.	  Specifically,	  in	  a	  study	  conducted	  by	  Nigro	  et	  al.	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in	  1990	  and	  in	  his	  previous	  study	  in	  1983,	  it	  was	  demonstrated	  that	  left	  ventricular	  function	   is	   normal	   in	   DMD	   patients	   under	   6	   years	   of	   age.	   However,	   there	   was	   a	  steady	   increase	   in	   the	   incidence	   of	   cardiomyopathy	  with	   age.	   By	   18	   years	   of	   age,	  there	  was	  evidence	  of	  contractile	  dysfunction	  with	  72%,	  and	  26%	  of	  patients	  having	  dilated	   cardiomyopathy	   and	   hypertrophic	   cardiomyopathy	   respectively.	  Furthermore	   they	   observed	   a	   decrease	   in	   fractional	   shortening,	   ejection	   fraction.	  (16,32,63,98).	   This	   is	   similar	   to	   the	   trend	   that	   was	   observed	   in	   my	  echocardiography	  pilot	  study.	  	  In	   other	   echocardiography	   studies	   involving	  DMD	  patients,	  Danlilowicks	   et	  al.	   (1980),	   Golberg	   et	   al.	   (1982),	   and	   Melacini	   et	   al.	   (1996)	   have	   found	   similar	  cardiac	   functional	   abnormalities.	   Danilowicks	   et	   al.	   (1980),	   observed	   dilated	   left	  ventricle	  in	  14	  of	  the	  36	  patients	  scanned.	  	  Moreover,	  ventricular	  relaxation	  was	  low	  in	  35	  out	  of	  the	  36	  patients.	  They	  also	  observed	  a	  decrease	  in	  the	  ejection	  fraction	  in	  30	   patients(67).	   Golberg	   et	   al.	   (1982)	   observed	   that	   most	   DMD	   patients	   have	  contraction	   abnormality,	  which	  was	   initially	   seen	   in	   the	  posterior	   free	  wall	   of	   the	  left	  ventricle(66).	  Melacini	  et	  al.	  (1996)	  found	  that	  there	  are	  two	  patterns	  of	  cardiac	  involvement	  in	  advanced	  DMD:	  abnormalities	  in	  the	  wall	  motion	  in	  the	  left	  ventricle	  in	  addition	  to	  left	  ventricular	  dilation	  with	  reduced	  ejection	  fraction	  (64).	  	  	  Overall,	   there	  are	  similarities	  and	  overlapping	  echocardiography	  findings	  in	  between	   our	   mouse	   model	   and	   the	   DMD	   condition	   observed	   in	   patients,	   which	  would	  make	  this	  model	  appropriate	  for	  assessing	  future	  treatments	  and	  monitoring	  the	  progression	  of	  disease.	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An	   obvious	   and	   necessary	   component	   of	  my	   thesis	   is	   a	   correlation	   of	   non-­‐	  invasive	   assessment	   of	   cardiomyopathy	   via	   DCE-­‐CT,	   PET-­‐FDG,	   and	  echocardiography,	  with	  histological	  analysis.	   In	   this	   study,	   I	   specifically	  conducted	  H&E	   staining	   to	   assess/quantify	   hypertrophy	   (cell	   size),	   and	  Masson’s	   Trichrome	  staining	  to	  assess/quantify	  myocardial	  fibrosis.	  I	   found	  that	  fibrosis	  is	  significantly	  higher	  in	  mdx:utrn	  -­‐/-­‐	  mice	  compared	  to	  age	  matched	  wild-­‐type	  mice	  at	  termination	  of	   study	   (Figure	   3.6)	   (9.5%	   for	  mdx:utrn	   -­‐/-­‐	   ,	   and	   1.7%	   for	  wild-­‐type	  mice).	   This	  demonstrates	   that	   cardiac	   fibrosis	   increases	   in	   the	  mdx:utrn	   -­‐/-­‐	  mice,	  whereas	   in	  wild	  type	  mice,	  fibrosis	  stays	  relatively	  constant	  .	  This	  is	  evidence	  of	  a	  deteriorating	  condition	   of	   myocardia	   mdx:utrn	   -­‐/-­‐	   mice.	   Quantification	   of	   cardiomyocyte	   size	  demonstrated	   significantly	   greater	   size	   in	  mdx:utrn	   -­‐/-­‐	  mice	   (average	   of	   34μm	   at	  end	  point)	  relative	  to	  age	  matched	  wild-­‐type	  mice	  (average	  of	  31μm)	  in	  myocardia	  harvested	  at	  the	  termination	  of	  the	  study.	  This	  further	  suggests	  that	  cardiomyocyte	  hypertrophy	  might	  indeed	  dominate	  the	  later	  stages	  of	  myocardial	  disease	  in	  mice.	  This,	   in	   conjunction	  with	   an	   increasing	   trend	   in	   cardiac	   fibrosis,	   likely	   accelerates	  the	  deterioration	  of	  function	  in	  the	  heart.	  	  Cardiac	   hypertrophy	   seems	   to	   dominate	   the	   focus	   of	   previous	   research	  rather	  than	  cardiomyocyte	  hypertrophy,	  and	  to	  our	  knowledge	  they	  have	  not	  been	  quantified	  before	  for	  DMD.	  However,	  Quinlan	  et	  al.	  (2004)	  mentioned	  that	  they	  have	  observed	  cardiomyocyte	  hypertrophy	  in	  mdx	  mice,	  but	  they	  have	  not	  presented	  the	  data	   for	   their	   finding(32).	   In	  a	  histopathology	   study	  of	   the	  heart	   in	  DMD	  patients,	  Frankel	   and	   Rosser	   (1976)	   have	   acknowledged	   presence	   of	   hypertrophy	   in	   the	  myocardium.	  However	  no	  quantification	  of	  this	  parameter	  was	  done	  (99).	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Our	  fibrosis	  quantification	  findings	  are	  supported	  by	  a	  previously-­‐mentioned	  study	  conducted	  by	  Chun	  et	  al.	  (2012),	  where	  fibrosis	  was	  detected	  in	  the	  outer	  regions	  of	  the	   ventricular	   wall	   and	   septum.	   By	   the	   age	   of	   15	   weeks,	   they	   observed	  approximately	   17	   times	   greater	   fibrosis	   than	   5	   weeks	   old	   mdx:utrn-­‐/-­‐	   mice(63).	  Similarly	  Spurney	  et	  al.	  (2008)	  and	  Quinlan	  et	  al.	  (2004)	  have	  quantified	  fibrosis	  in	  mdx	  mice.	   Spurney	   et	   al.	   (2008)	   have	   shown	   that	   there	   is	   approximately	   6	   times	  greater	   fibrosis	   in	   left	   ventricular	   myocardium	   of	   9-­‐10	   month	   old	   mdx	   mice	  compared	   to	   the	  wild-­‐type	  mice	   (100).	   Through	   quantifying	   fibrosis	   on	   17	  weeks	  old	   mdx	   mice,	   Quinlan	   et	   al.	   (2004)	   have	   shown	   almost	   4	   times	   greater	   fibrosis	  (with	  mdx	  mice	  having	  total	  8%	  fibrosis)	  in	  the	  heart	  compared	  to	  the	  age	  matched	  wild-­‐type	  mice.	  Also,	  they	  mentioned	  that	  there	  is	  a	  patchy	  pattern	  of	  fibrosis,	  which	  are	  evenly	  distributed	  and	  involve	  endocardium,	  myocardium	  and	  pericardium	  (32).	  	  	  There	   are	   overlapping	   similarities	   in	   histological	   quantification	   findings	  between	  the	  human	  DMD	  condition	  and	  our	  mouse	  model.	  Overall,	   it	  appears	   that	  fibrosis	  is	  more	  extensive	  in	  DMD	  patients.	  Autopsy	  studies	  in	  DMD	  (99,101)	  did	  not	  quantify	   the	   degree	   of	   the	   fibrosis,	   however	   their	   narrative	   description	   suggests	  presence	   of	   severe	   fibrosis	   in	   areas	   of	   posteriobasal,	   anterolatleral,	   and	  inferoposterior	  	  of	  left	  ventricular	  walls.	  	  
4.1	  Conclusion	  	  
Most	  significant	  findings	  of	  this	  thesis	  are	  as	  follows:	  1) Dynamic	   contrast	   enhanced	   computed	   tomography	   (DCE-­‐CT),	   and	   positron	  emission	   tomography	   (PET-­‐FDG)	   demonstrates	   that	   myocardial	   perfusion	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(blood	   flow	   and	   blood	   volume)	   and	   metabolism	   is	   not	   affected	   in	   the	  mdx:utrn-­‐/-­‐	  mice	  relative	  to	  healthy	  wild-­‐type	  mice.	  2) Pilot	   echocardiography	  data	   shows	  possible	  decrease	   in	   cardiac	   function	  of	  mdx:utrn	   -­‐/-­‐	   compared	   to	   age	   matched	   wild-­‐type	   by	   15-­‐17	   weeks	   of	   age.	  Decreasing	  trend	  was	  observed	  in	  ejection	  fraction	  and	  fractional	  shortening,	  alongside	   increasing	   trend	   in	   systolic	   left	   ventricular	   internal	   diameter	   in	  mdx:utrn	   -­‐/-­‐	   mice.	   These	   findings	   supports	   previous	   studies	   and	   possibly	  validates	  utility	  of	  echo	  to	  reproducibility	  assess	  cardiac	  disease	  progression	  in	  mouse	  models.	  3) Histological	   quantification	   analysis	   shows	   significant	   increase	   in	   cardiac	  fibrosis	  in	  mdx:utrn	  -­‐/-­‐	  mice	  compared	  to	  wild-­‐type	  at	  termination	  of	  study.	  Also	   cardiomyocytes	   size	   (cell	   size)	   quantification	   showed	   that	   there	   is	  significant	  increase	  in	  cell	  size	  in	  mdx:utrn-­‐/-­‐	  mice	  	  at	  the	  end	  point	  of	  study.	  Histological	   quantification	   analysis	   allows	   important	   correlation	   to	   non-­‐invasive	  assessment	  of	   cardiomyopathy,	  using	   imaging	  methods	   that	  are	  as	  of	  yet	  unvalidated	  in	  small	  animals	  preclinical	  models.	  	  
4.2	  Limitations	  
One	   of	   the	   limitations	   of	   our	   study	   may	   have	   been	   my	   utilization	   of	   clinical	   CT.	  Clinical	  CT	  provided	  me	  with	   image	   slices	  of	   1.25	  mm	   thickness,	  which	  might	  not	  have	   been	   sufficient	   for	   the	   detailed	   analysis	   of	   the	   mouse	   myocardium.	  Furthermore,	   this	   slice	   thickness	   might	   have	   provided	   me	   with	   inaccurate	  calculation	   of	   cardiac	   volume,	   as	   few	   slices	   were	   available	   to	   be	   analyzed.	   In	  addition,	   clinical	   CT	   provided	  me	  with	   transaxial	   resolution	   that	   limited	   accurate	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delineation	   of	   the	   boundaries	   of	   the	   chambers;	   hence	   calculation	   of	   the	   whole	  cardiac	   volume	  was	  done	   (calculation	   of	   left	   ventricular	   volume	  would	  have	  been	  more	  optimal	  as	  dilated	  cardiomyopathy	  largely	  effects	  the	  left	  ventricle).	  	  	   Another	  limitation	  of	  the	  study	  involved	  echocardiography.	  	  Measurement	  of	  cardiac	   ejection	   fraction	   was	   not	   precise,	   as	   it	   involved	   approximate	   volumetric	  calculation	   of	   the	   left	   ventricle	   using	   Teichholz	   equation.	   In	   addition,	   variability	  introduced	   by	   the	   operator	   could	   affect	   the	   results.	   Accuracy	   of	   the	   parameter	  measurements	   in	   the	   longitudinal	   study	   was	   dependent	   on	   the	   expertise	   of	   the	  operator	   to	   obtain	   consistent	  M-­‐mode	   beam	   placement	   for	   the	   echocardiography	  parameter	  measurements	  at	  different	  time	  points.	  In	  addition,	  survival	  rate	  of	  the	  mice	  could	  be	  affected	  by	  the	  radiation	  given	  during	  the	  scans	  to	  the	  mice	  via	  CT	  and	  PET.	  	  However,	  since	  wild-­‐type	  mice	  did	  not	  exhibit	  overt	  cardiac	  muscle	  damage,	  this	  can	  be	  possibly	  ruled	  out.	  
4.3	  Future	  Directions	  	  
Some	  future	  directions	  of	  our	  lab’s	  research	  may	  be	  to	  use	  the	  findings	  of	  this	  study	  as	   a	   baseline	   to	   assess	   the	   efficacy	   of	   various	   treatments	   and	   to	   improve	   our	  fundamental	  understanding	  of	  the	  progression	  of	  the	  disease.	  In	  the	  near	  future,	  our	  group	  is	  also	  considering	  the	  use	  of	  gated	  micro	  computed	  tomography	  to	  assess	  its	  capability	   to	   characterize	   the	   progression	   of	   cardiomyopathy	   in	   mdx:utrn	   -­‐/-­‐	   vs.	  wild-­‐type	  mice.	   Gated	  micro	   computed	   tomography	   could	   be	   utilized	   to	   calculate	  ejection	   fraction	   with	   higher	   degree	   of	   accuracy	   by	   actual	   ventricular	   volume	  measurement	   (region	   growing	   using	   seed	   and	   thresholding)	   at	   the	   two	   phases	   of	  diastole	   and	   systole.	   Furthermore,	   our	   group	   is	   considering	   performing	   a	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reproducibility	   study	   (involving	   scanning	   of	   healthy	   mice	   in	   time),	   to	   assess	  consistency	  of	  the	  echocardiography	  measurements.	  	  In	   addition	   a	   statistical	   power	   analysis	  will	   be	   conducted	   in	   near	   future	   to	  determine	  the	  appropriate	  sensitivity	  of	  the	  three	  modalities	  used	  in	  the	  study.	  The	  results	  of	  this	  would	  aid	  us	  in	  choosing	  the	  optimal	  modality	  that	  can	  be	  utilized	  for	  assessing	  and	  monitoring	  of	  the	  success/failure	  of	  future	  therapeutics.	  Furthermore,	  our	   group	   is	   also	   considering	   other	   means	   of	   assessing	   myocardial	   disease	  progression	   in	  our	  murine	  model	  of	  DMD	  via	  positron	  emission	  tomography	  using	  new	  myocardial	   perfusion	   tracers.	   Our	   long-­‐term	   goal	   is	   to	   use	   these	   findings	   to	  determine	   the	  efficacy	  of	  stem	  cell	   therapy	   in	  regeneration	  of	  cardiomyocytes.	  We	  are	  hoping	   that	  current	  and	   future	   findings	  can	  be	   translated	   to	  better	   treatments	  and	  more	  accurate	  monitoring	  of	  disease	  progression	  in	  DMD	  patients.	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  From	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  presentation:	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